Shitij Kapur Dean and Head of School King’s College London Kapur's CV.pdf · Shitij Kapur Dean...

Shitij Kapur .... CV... of 50.

Shitij Kapur

Dean and Head of School

Professor of Schizophrenia, Imaging and Therapeutics

Institute of Psychiatry, King’s College London

De Crespigny Park, London SE5 8AF

UK Tel: +44 20 7848 0424

Email: [email protected] PREVIOUS APPOINTMENTS

2007 – 2010 Vice Dean (Research) Inst of Psychiatry, King’s College London 2003 - 2007 VP and Chief of Research CAMH, Toronto 2003 - 2007 Professor Dept. of Psychiatry, University of Toronto. 2001 - 2007 Canada Research Chair University of Toronto, Toronto, Canada 1998 - 2007 Graduate Faculty Institute of Medical Science, Univ. of Toronto. 1995 - 2007 Research Scientist The PET Centre, CAMH, Toronto. 2000 -- 2003 Section Head Schizophrenia Research, CAMH, Toronto. 1999 -- 2003 Program Leader Eli Lilly-CAMH Therapeutic Neuroscience Program. 1999 – 2003 Associate Professor Dept. of Psychiatry, University of Toronto. 1997 – 2000 Deputy Head for Research Schizophrenia Program, Clarke/CAMH, Toronto. 1997 – 1999 Assistant Professor Dept. of Psychiatry, University of Toronto. 1994 -- 1998 Research Scientist Rotman Research Institute, Toronto.

EDUCATION AND TRAINING

Undergraduate 1980-1982 Pre-Medical DAV College, Chandigarh, India.

Medical School 1982-1988 MBBS All India Institute of Medical Sciences

Residency Training 1988-1992 Psychiatry University of Pittsburgh. 1993-1994 Psychiatry University of Toronto.

Fellowship 1992-1996 Schizophrenia The Clarke Institute, University of Toronto

PhD 1992-1996 Neuroscience Institute of Medical Science, University of Toronto.


Specialist Certification (In Psychiatry) 1994: Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC). 1994: Diplomate of the American Board of Psychiatry and Neurology (ABPN).

License to Practice Medicine 1988-1992 Educational License (MT - 021393- T) Pennsylvania, USA. General License (MD - 044784 - L) Pennsylvania, USA. 1992-present Independent License (CPSO - 65718) Ontario, Canada.

HONOURS AND AWARDS Fellow of the Academy of Medical Sciences, UK (2009) Robert Sommer Award, University of Geissen, Germany (2008) Distinguished Fellow of the American Psychiatric Association, USA (2007) Joel Elkes Award of the American College of Neuropsychopharmacology (ACNP), 2007. Paul Janssen award of the Collegium Internationale Neuropsychopharmacologicum (CINP), 2006 AE Bennet Award of the Society for Biological Psychiatry, 2006 Innovation in Neurospsychopharmacology Award, Cdn. College of Neuropsychopharmacology, 2004

Outstanding Academician Award, Indo-American Psychiatric Association, USA, 2004

Paul Garfinkel Award for Best Fellowship Supervisor, Dept. Psychiatry, University of Toronto, 2002.

The Young Explorer’s Award of the Canadian Institute of Advanced Research, 2002.

The Research Prize from the World Congress of Biological Psychiatry, Berlin, 2001.

Best Poster Award, Collegium Internationale Neuropsychopharmacologicum, 2000.

Young Investigator Award of the Canadian College of Neuropsychopharmacology, 1999.

Honourable Mention, Gerald Klerman Award for Outstanding Clinical Research, NARSAD, 1999.

John Cleghorn Newly Established Faculty Researcher Prize, Psychiatry, Univ. of Toronto. 1998.

Frist Award in Neuropsychopharmacology, University of Toronto, 1997.

Siminovitch-Salter Award for PhD research, Institute of Medical Science, Univ. of Toronto, 1997.

Young Investigator Award, International Congress on Schizophrenia Research, 1997.

NARSAD Young Investigator Award. NARSAD, USA. 1995

Honorable mention as APA-Wisnewski Young Psychiatrist Research Award, APA, 1993-1994.

Max A. Gordon Research Prize of the Rotman Research Institute, University of Toronto, 1994.

APA-Lilly Psychiatric Research Fellowship of the American Psychiatric Association. 1992.

Research Fellowship from the Ontario Mental Health Foundation, Canada. 1992-1994.

Society for Biological Psychiatry-Dista Fellowship Award of the Society for Biological Psychiatry.1992.

Laughlin Award, Western Psychiatric Institute and Clinic, University of Pittsburgh. 1992.

William C Menninger Award for Research, Central Neuropsychiatric Association, 1992.

Sol Ginsburg Fellowship to the Group for the Advancement of Psychiatry. USA. 1991-1993.

President's Gold Medal for Best Medical Graduate, All India Institute of Medical Sciences, India. 1987.

Best All Round Student Award, All India Institute of Medical Sciences, India. 1987.

University Gold Medal for first position in Pre-Medical, Panjab University, India. 1982.

University Gold Medal for first position in Pre-University, Panjab University, India. 1981.

National Talent Scholar, India.1980-1987.


SCIENTIFIC AND PROFESSIONAL AFFILIATIONS AND ACTIVITIES Editorial Activities Editorial Board (2002 onwards), Schizophrenia Research Editorial Board (2005 onwards), Schizophrenia Bulletin Editorial Board (2005 onwards), BMC Psychiatry Editorial Board (2007 onwards), Archives of General Psychiatry Editorial Board (2009 onwards), World Journal of Biological Psychiatry Associate Editor (2002-2005), American Journal of Psychiatry Editorial Board (2003-2005), Neuropsychopharmacology Associate Editor (2006 onwards), Psychiatry Domain - The Scientific World JOURNAL Review Committee Member Behavioural Sciences ‘A’ Committee, MRC/CIHR of Canada (1999-2003) Membership in Professional Organizations Collegium Internationale Neuropsychopharmacologicum European College of Neuropsychopharmacology American College of Neuropsychopharmacology American Psychiatric Association Canadian College of Neuropsychopharmacology Society for Biological Psychiatry (past) Society for Neuroscience (past) Service in Professional Organizations Boart of Trustees, Schizophrenia International Research Society (2010-2014) Secretary of the CINP (2009-2012) Member of the Advisory Board, Founding Board Member, Schizophrenia International Research Society Member, Scientific Program Committee, Society of Biological Psychiatry (1999-2002) Councillor, Canadian College of Neuropsychopharmacology (2001 - 2004) Scientific Program Advisor, International Congress of Schizophrenia Research (2004) External Referee for Grants Medical Research Council, UK Medical Research Council of Canada, Canada Canadian Institutes of Health Research, Canada The Canadian Psychiatric Research Foundation, Canada The Ontario Mental Health Foundation, Canada The Stanley Research Foundation, USA The National Institute of Mental Health, NIH, USA Regular External Referee for Manuscripts American Journal of Psychiatry; Archives of General Psychiatry; Biological Psychiatry Neuropsychopharmacology, Schizophrenia Research, Schizophrenia Bulletin,


Psychopharmacology. Occasional External Referee for Manuscripts Journal of Cerebral Blood Flow and Metabolism; Cerebral Cortex; Journal of Nuclear Medicine Proceedings of the National Academy of Sciences; Psychosomatics; Science.

RESEARCH AWARDS

Career Support Awards APA-Lilly Psychiatric Research Fellowship 1992-1993 Support: US$ 35,000 OMHF Research Fellowship 1993-1995 Support: $ 32,000/yr MEDICAL RESEARCH COUNCIL 1995-2000 Clinician Scientist Award (Phase I and Phase II) Support: $ 55,000/yr (salary) + 40,000/yr (operating allowance) Canada Research Chair (Tier II Award) 2001-2006 Clinician Scientist Award (Phase I and Phase II) Support: $ 50,000/yr (salary) + 50,000/yr (operating allowance) Canada Research Chair (Tier II Award, Renewed and given up) 2006-2011 Support: $ 50,000/yr (salary) + 50,000/yr (operating allowance) Operating Grants (Peer-reviewed) PET studies of episodic memory. 1995-1996 SWEDISH COUNCIL FOR HEALTH RESEARCH (HFSR) Total Support: $ 70, 000 PI: Lars Nyberg; Co-Inv.: L-G Nilsson, E Tulving, S Kapur, R McIntosh, S Houle A PET study of the relationship between D2-dopamine receptor occupancy and clinical response. NARSAD, USA 1995-1997 Total Support: $ 80,000. PI: S Kapur Amoxapine as an atypical antipsychotic: a PET analysis. 1997-1998 CANADIAN PSYCHIATRIC RESEARCH FOUNDATION Total Support: $ 30, 000 PI: S Kapur Co-Investigators: RB Zipursky, G Remington, S Houle Positron Emission Tomography Imaging of 5-HT2 receptors in depression before and after treatment as compared to healthy subjects. 1997-1998 CANADIAN PSYCHIATRIC RESEARCH FOUNDATION Total Support: $ 30, 000 PI: S Kennedy


Co-Investigators: J Meyer, S Kapur, S Houle Amoxapine as an antipsychotic – a clinical PET study. 1998-1999 DEAN’S FUND COMPETITION FOR NEW STAFF – UNIVERSITY OF TORONTO Total Support: $ 10,000 PI: S Kapur A comparative positron emission tomography study of 5HT2 receptors in patients with major depression (before and after treatment) and in healthy volunteers. 1997-2000 MEDICAL RESEARCH COUNCIL OF CANADA Total Support: $150, 828 PI: S Kennedy Co-Investigators: J Meyer, S Kapur, S Houle

5-HT1A receptors in Schizophrenia: a PET Investigation 1998-2001 EJLB FOUNDATION SCHOLAR PROGRAM Total Support: $ 300,000 PI: S Kapur Dynamic aspects of drug-receptor interaction: implications for antipsychotic action. STANLEY FOUNDATION, USA 1999-2001 Total Support: $ 140, 000 PI: S Kapur Co-Investigators: Phil Seeman, Glen Baker. PET investigations of endogenous dopamine and clinical response in Schizophrenia MEDICAL RESEARCH COUNCIL OF CANADA 1999-2002 Total Support: $ 318, 828 PI: S Kapur Co-Investigators: R Zipursky Amoxapine as treatment for Schizophrenia – a proof of principle study. 1999-2000 STANLEY FOUNDATION Schizophrenia Treatment Network, USA Total Support: $ 22, 000 PI: S Kapur Co-Investigators: R Apiquian-Guitart, E Ulloa, H Nicolini (Inst. Of Psychiatry, Mexico) A Canadian Consortium for Understanding Antipsychotic Action – CIHR Opportunity Fund. MEDICAL RESEARCH COUNCIL OF CANADA 1999-2000 Total Support: $ 27, 150 PI: S Kapur Co-Investigators: Bob Zipursky, Phil Seeman, Glen Baker. PET study of 5-HT1A receptors in Alzheimer’s Disease 2000-2002 ALZHEIMER’S ASSOCIATION, USA. Total Support: $ 145, 000 PI: Krista Lanctot and S Kapur (Co-PI) Co-Investigators: N Herrmann, S E Black.


The pharmacological basis of atypical antipsychotic activity – a new hypothesis CANADIAN INSTITUTES OF HEALTH RESEARCH 2001-2006 Total Support: $ 767, 375 PI: S Kapur Co-Investigators: RB McCllelland, JN Nobrega, P-P Rompré. Amoxapine as an atypical antipsychotic: A comparative study vs. risperidone. 2001-2003 STANLEY FOUNDATION Schizophrenia Treatment Network, USA Total Support: $ 107, 388 PI: R Apiquian-Guitart and S Kapur Co-Investigators: E Ulloa, A Fresan, H Nicolini (Inst. Of Psychiatry, Mexico) Infrastructure for Translational Research in Therapeutic Neuroscience: Bridging Clinical Findings to Animal Models using PET Imaging. 2001-2004 CANADA FOUNDATION FOR INNOVATION Total Support: $ 247, 708 PI: S Kapur Augmentation of Clozapine Partial Responders with Tetrabenazine 2002-2005 STANLEY FOUNDATION Schizophrenia Treatment Network, USA Total Support: $ 276, 000 PI: G Remington Co-Investigator: S Kapur A study of cortical inhibition using TMS. 2001-2003 CPRF NEW INVESTIGATOR AWARD to Daskalakis Total Support: $ 60, 000 PI: Z Daskalakis Co-Investigator: S Kapur, R Chen, B Christensen. Imaging endogenous dopamine levels with in vivo [11C]-raclopride displacement studies: Understanding the true mechanisms. 2002-2005 CANADIAN INSTITUTES OF HEALTH RESEARCH Total Support: $ 297, 550 PI: N Ginovart Co-Investigators: S Kapur, S Houle. The development of an integrated computational neuroscience program to understand human mental function. 2002-2007 CANADIAN INSTITUTES OF HEALTH RESEARCH Total Support: $ 1,210,000 PI: AR McIntosh Co-Investigators: S Kapur, Mark Henkelman; Simon J Graham; Paul Fletcher; Sue Becker; Richard Zemel; Ron S. Dembo Decoding Schizophrenia – putting the pieces together: Linking Genes, Neurochemistry, Cognition, Affect and Neural Networks. 2002-2006 ONTARIO MENTAL HEALTH FOUNDATION – SPECIAL INITIATIVE Total Support: $ 984, 670


PI: S Kapur Co-Investigators: Paul Fletcher; Sue Becker; Teresa Tallerico, Phil Seeman.


The effect of antipsychotics on maternal behavior – identifying the underlying behavioural and neurobiological mechanisms. 2002-2004 NARSAD Independent Investigator Award Total Support: $ 146, 700 PI: S Kapur Collaborator: Alison Fleming Combining Dopamine D1 Agonism and D2 Antagonism: In Search for the Next Generation of Antipsychotics. 2004-2006 STANLEY MEDICAL RESEARCH INSTITUTE Total Support: $ 113,105 PI: S Kapur Co-PI: David Mamo Schizophrenia, reward learning and reward prediction errors – A study using computational models and event related fMRI. 2004-2007 CANADIAN INSTITUTES OF HEALTH RESEARCH Total Support: $ 335,818 PI: S Kapur Co-Investigators: Robert Zipursky, Sue Becker, David Mikulis Natural Health Products in Primary Psychotic Disorders: Use & Attitudes. 2004-2005 NATURAL HEALTH PRODUCTS RESEARCH PROGRAM (HEALTH CANADA) Total Support: $66,090 PI: S Kapur Co-Investigators: David Mamo, Samuel Noh, Heather Boon Treating Refractory Auditory Hallucinations in patients with Schizophrenia through enhanced cortical inhibition 2004-2006 NARSAD Young Investigator Award Total Support: $ 80, 000 PI: Jeff Daskalakis Collaborators: Robert Chen, S Kapur. PET imaging of the dopamine D2-high affinity state in humans CANADIAN INSTITUTES OF HEALTH RESEARCH 2005-2008 Total Support: $314,826 PI: Alan Wilson Co-PI: Nathalie Ginovart Co-Investigators: S Kapur, Sylvain Houle A PET Study of L-Stepholidine: In Search of a Treatment with Combined D1 agonist – D2 antagonist Properties STANLEY FOUNDATION MEDICAL RESEARCH INSTITUTE 2006-2007 Total Support: $ 292,468 PI: D Mamo Co-Investigator: S Kapur


A [11C]-(+)-PHNO Study in Tobacco Smokers CTCRI - CANADIAN INSTITUTES OF HEALTH RESEARCH 2007-2008 Total Support: $ 50,000 PI: B Le Foll Co-Investigators: S Kapur, L Zawertailo, U Busto, A Wilson The functionally-relevant high affinity state of the dopamine D2 receptor in schizophrenia: Their role in illness and treatment. CANADIAN INSTITUTES OF HEALTH RESEARCH 2006-2010 Total Support: $ 402,000 PI: S Kapur Co-PI: R Zipursky Co-Investigators: A Wilson, Ofer Agid, Romina Mizrahi, Ariel Graff Behavioral Stabilizers – Understanding the concept, its underlying mechanism and potential utility CANADIAN INSTITUTES OF HEALTH RESEARCH 2006-2011 Total Support: $ 595,625 PI: S Kapur Co-Investigators: P Fletcher, J Nobrega, P-P Rompre. Prefrontal Cortex in Cognitive Deficit Models of Schizophrenia CANADIAN INSTITUTES OF HEALTH RESEARCH 2006-2010 Total Support: $ 379,400 PI: P Fletcher Co-Investigators: S Kapur, J Nobrega. Strategic Appointments Scheme (Bench to Bedside Studies of Antipsychotics) MEDICAL RESEARCH COUNCIL (UK) 2008-2011 Total Support: £1,000,000 PI: S Kapur NEWMEDS – Novel Methods leading to New Medications in Depression and Schizophrenia EU-EFPIA Innovative Medicines Initiative 2009-2014 Overall Coordinator and Industry Lead: Tine Bryan Stensbol (Lundbeck) Managing entity and Academic Lead: S Kapur Total EU Funding: € 8,215,165 KCL Fudning: € 2,788,159 Optimization of Treatment and Management of Schizophrenia in Europe EUFP7 Program 2010-2016 Total Funding: € 11,186,830 KCL Funding:€ 1,750,922 PI: Kahn Vice-Chair and Lead PI for KCL: S Kapur


Investigator-Initiated Industry-supported Research Grants These were projects were initiated or actively designed by the investigator/s and supported by the industry. In all these cases we retained academic control of publishing manuscripts/abstracts. D2-dopamine and 5-HT2-serotonin receptor occupancy in patients on stable doses of risperidone: a PET study. 1995-1997 Janssen Research Foundation Total Support: $ 126,200 Co-Principal Investigators: S Kapur & G Remington An open-label study assessing the in vivo 5-HT2 and D2 receptor occupancy of Olanzapine using PET in patients with Schizophrenia. 1996-1997 Eli Lilly Canada, Inc. Total Support: $ 178,000 Principal Investigator: S Kapur Co-Investigators: G Remington, RB Zipursky, P Roy, S Houle Combining loxapine and cyproheptadine for unique clozapine-like 5-HT2/D2 profile: A PET study. Wyeth Ayerst Canada Inc. 1996-1997 Total Support: $ 34,500 Principal Investigator: S Kapur Co-Investigators: RB Zipursky, G Remington, S Houle 5-HT2 antagonism of nefazadone: relevance to the therapeutics of depression and schizophrenia – a PET study. 1997-1998 Bristol Myers Squibb Total Support: $ 125,25 Principal Investigator: S Kapur Co-Investigators: R Cho, S Kennedy, RB Zipursky. Understanding the mechanism of action of novel antipsychotic agent Seroquel (ICI 204,636) using 5-HT2 and D2 receptor PET imaging. 1997-1998 Zeneca Pharmaceuticals Total Support: $ 171,600 Principal Investigator: S Kapur Co-Investigators: RB Zipursky, S Houle. A single-site PET Study to investigate the D2 and 5HT2 occupancy and its relationship to clinical outcome. Eli Lilly and Co. 1997-1999 Total Support: $ 360,950 Co Principal Investigators: S Kapur and RB Zipursky Differential effects of continuous vs. transient dopamine receptor blockade: Implications for understanding antipsychotic action. 1999-2000 AstraZeneca Canada Total Support: $ 98,150 Principal Investigator: S Kapur


Investigating the prolonged receptor effects of Olanzapine: a PET study. 1999-2000 Eli Lilly Co. Total Support: $ 96,484 Principal Investigator: S Kapur Co-Investigators: RB Zipursky, Gary Remington. Brain Receptor Kinetics – Measurement and Functional Consequences as Relevant to Development of Psychotropics 2000-2001 Eli Lilly Co. Total Support: $ 121,800 Principal Investigators: S Kapur and Phil Seeman. The development of a novel, potentially antipsychotic, compound. 2000-2002 NeuroMolecular Inc. Total Support: $ 626,000 Principal Investigator: S Kapur Co-Investigators: Phil Seeman, Robert McClleland. An open-label study assessing the in-vivo D2 occupancy of IM Olanzapine Depot using PET imaging in patients with Schizophrenia. 2001-2003 Eli Lilly Co. Total Support: $ 413,736 Principal Investigators: S Kapur and Gary Remington. Co-Investigators: CS Shammi, J Daskalakis, G Papatheodorou. A single centre PET study to determine the occupancy of EMD 281-014 at cortical 5-HT2 receptors. EMD Pharmaceuticals 2002-2003 Total Support: $ 237,146 Principal Investigator: S Kapur Animal models of schizophrenia: what do they predict and what to make of it? Eli Lilly Co. 2002-2004 Total Support: $ 315,418 Principal Investigator: S Kapur Co-Investigators: P Fletcher and J Nobrega. Single Centre Positron Emission Tomography (PET) Examination for RIS-USA-305 Janssen Pharmaceutica Products 2002-2004 Total Support: $ 104,868 Principal Investigator: S Kapur Co-Investigators: G Remington Central 5-HT1A, 5-HT2A and D2-receptor occupancy by Aripiprazole in patients with Schizophrenia: A PET Study 2004-2005 Bristol-Myers Squibb Canada Co. Total Support: $ 322,380 Principal Investigator: S Kapur


Dopamine Stabilizers – Understanding their Mechanism Eli Lilly and Co. 2004-2005 Total Support: $ 85,995 Prinicipal Investigator: S Kapur Comparing agonist versus antagonist radioligands in their ability to report drug-induced occupancy Glaxo Smith-Kline, Canada. 2005-2006 Total Support: $ 102,800 Prinicipal Investigator: S Kapur Developing neuroimaging markers for psychotropic drug development Astra Zeneca 2005-2006 Total Support: $ 152,800 Prinicipal Investigator: S Kapur Co-Investigator: Jimmy Jensen


PUBLICATIONS

*: First author was a research trainee under supervision or co-supervision.

Refereed Articles: 1. Kapur S, Pandav CS: Predicting 24 hour metabolite excretion from a single casual urine

sample: A new approach. Indian Journal of Pediatrics, 1985, 05:82-86. 2. Pandav CS, Kapur S, Karmarkar MG: Methods for evaluation iodine intake: A reassessment.

Indian Journal for Community Medicine, 1986, 11:223-227. 3. Kapur S, Keshavan MS: Neuroleptic Malignant Syndrome - A clinical perspective, Family

Practice, 12:37-53, 1990. 4. Kapur S, JJ Mann: The emergence of suicidal ideation and behavior during antidepressant

pharmacotherapy. Archives of General Psychiatry, 48:1027-1033, 1991. 5. Keshavan MS, Kapur S, Pettegrew JW: Magnetic resonance spectroscopy in psychiatry:

potential, pitfalls and promise. American Journal of Psychiatry, 148:976-985, 1991. 6. Kapur S, Ganguli R, Ulhrich, RS, Raghu, U: Use of Random-Sequence Riboflavin as a marker

of Medication Compliance in Chronic Schizophrenics. Schizophrenia Research, 6:49-53, 1992. 7. Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R: Clozapine for the Treatment of

Adolescents with Schizophrenia. American Journal of Child and Adolescent Psychiatry, 31:160-164, 1992.

8. Kapur S, Mann JJ: The Role of the Dopamine System in Depression. Biological Psychiatry,

32: 1-17, 1992. 9. Kapur S, Mieczkowski T, Mann JJ: Antidepressant medications and the relative risk of suicide

and suicide attempt. Journal of the American Medical Association, 268 (24): 3441-3445, 1992.

10. Kapur S, Austin MC, Underwood MD, Arango VA, Mann JJ: Electroconvulsive shock increases

tyrosine hydroxylase and NPY mRNA in the rat locus coeruleus. Molecular Brain Research, 18: 121-126, 1993.

11. Goldman HH, Adler DA, Berlant J, Docherty J, Dorwart R, Ellison JM, Pajer K, Siris S, Kapur S:

The case for services-based approach to payment of mental illness under National Health Care reform. Hospital and Community Psychiatry, 44(6): 542-545, 1993.

12. Kapur S, Craik FIM, Tulving E, Wilson A, Brown GM, Houle S: Neuroanatomical correlates of

encoding in episodic memory: Levels of processing effect. Proceedings of the National Academy of Sciences USA, 91: 2008-2011, 1994.

13. Tulving E, Kapur S, Craik FIM, Moscovitch M, Houle S: Hemispheric encoding/retrieval

asymmetry in episodic memory: Positron Emission Tomography Findings. Proceedings of the National Academy of Sciences USA, 91: 2012-2015, 1994.

14. Tulving E, Kapur S, Markowitsch H, Craik FIM, Habib Reza, Houle S: Neuroanatomical

correlates of retrieval in episodic memory: Auditory sentence recognition. Proceedings of the


National Academy of Sciences USA, 91: 2016-2020, 1994. 15. Kapur S, Meyer J, Wilson A, Houle S, Brown GM: Modulation of cortical neuronal activity by a

serotonergic agonist: a PET study in humans. Brain Research, 646: 292-294, 1994. 16. Kapur S, Meyer J, Wilson AA, Houle S, Brown GM: Activation of specific cortical regions by

apomorphine -- a 15O-labeled water PET study in humans. Neuroscience Letters, 176: 21-24, 1994.

17. Kapur S, Houle S, Brown GM: PET in Psychiatry: New sights, New Insights. Jeffersen Journal

of Psychiatry, 12: 58-74, 1994. 18. Houle S, Kapur S, Rose R, Hussey D, Wilson D: Absence of residual effects after

physiological stimulation of the visual and motor cortex — an [15O]-H2O PET study in humans. Nuclear Medicine Communications, 15: 860-864, 1994.

19. Kapur S, Rose R, Liddle PF, Zipursky RB, Houle S, Stuss D, Brown GM, Tulving E: The role of

the left prefrontal cortex in verbal processing: semantic processing or willed action? Neuroreport, 5: 2193-2196,1994.

20. Tulving E, Markowitsch HJ, Kapur S, Habib R, Houle S: Novelty encoding networks in the

human brain: Positron Emission Tomography data. NeuroReport, 5: 2525-2528, 1994. 21. Mann JJ, Kapur S: Elucidation of the biochemical basis of the antidepressant action of

electroconvulsive therapy in human studies. Psychopharmacology Bulletin, 30(3): 445-453, 1994.

22. Moscovitch M, Kapur S, Köhler S, Houle S: Dissociation of the neural pathways subserving

retrieval of memory for spatial-location and objects. Proceedings of the National Academy of Sciences USA, 92: 3721-3725, 1995

23. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S: The D2 dopamine receptor

occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Science, 57(10PL): 103-108, 1995.

24. Mann JJ, Kapur S: Dopamine and depression. Clinical Neuropharmacology, 18(Suppl 1): 52-

65, 1995. 25. Kapur S, Hussey D, Wilson D, Houle S: The statistical power of [15O]-water PET activation

studies of cognitive processes. Nuclear Medicine Communications, 16: 779-784, 1995. 26. Kapur S, Craik FIM, Jones C, Brown GM, Houle S, Tulving E: The role of the right prefrontal

cortex in memory retrieval: A PET study. NeuroReport, 6: 1880-1884, 1995. 27. Kohler S, Kapur S, Moscovitch M, Winocur G, Houle S: Dissociation of pathways for object and

spatial vision: A PET study in humans. NeuroReport, 6: 1867-1870, 1995. 28. Nyberg L, Tulving E, Habib R, Nilsson L-G, Kapur S, Houle S, Cabeza R, McIntosh AR:

Functional brain maps of retrieval mode and recovery of episodic information. NeuroReport, 7: 249-252, 1995.

29. Kapur S, Remington G: The Serotonin-Dopamine interaction and it relevance to Schizophrenia.

American Journal of Psychiatry, 153: 466-476, 1996.


30. Remington G; Kapur S: Neuroleptic-induced extrapyramidal symptoms and the role of combined serotonin-dopamine antagonism. Journal of Clinical Psychiatry, 14 (1): 14:24, 1996.

31. Kapur S: 5-HT2 antagonism and EPS: Is there a causal connection? Psychopharmacology,

124 (1-2): 35-39, 1996. 32. Meyer, JH, Kapur S, Wilson AA, Houle S, Brown GM: Activation of the frontal and temporal

cortex by intravenous d-fenfluramine: an [15O]-H2O study in humans. Neuroscience Letters, 207 (1): 25-28, 1996.

33. Kapur S, Remington G, Jones C, DaSilva J, Wilson AA, Houle S, Zipursky RB: High levels of

dopamine D2 receptor occupancy with low dose haloperidol treatment: A PET study. American Journal of Psychiatry, 153: 948-950, 1996.

34. Mackinnon C, Kapur S, Hussey D, Verrier M, Houle S, Tatton W: Contributions of the mesial

frontal cortex to the premovement potentials associated with intermittent hand movement in humans. Human Brain Mapping, 4: 1-22, 1996.

35. Kapur S, Zipursky RB, Jones C, Remington G, DaSilva J, Wilson AA, Houle S: The D2 receptor

occupancy profile of loxapine determined using PET. Neuropsychopharmacology, 15: 562-566, 1996.

36. Kapur S, Tulving E, Cabeza R, McIntosh AR, Houle S, Craik FIM: The neural correlates for

intentional learning of verbal materials: a PET study in humans. Cognitive Brain Research, 4:243-249, 1996.

37. *Gemar MC, Kapur S, Segal Z, Brown GM, Houle S: Effects of self-generated sad mood on

regional cerebral activity - a PET study in normal subjects. Depression, 4: 81-88, 1996. 38. *Cabeza R, Grady CL, Nyberg L, McIntosh AR, Tulving E, Kapur S, Jennings JM, Houle S,

Craik FIM: Age-related differences in neural activity during memory encoding and retrieval: a PET study. Journal of Neuroscience, 17(1):391-400, 1997.

39. *Cabeza R, Kapur S, Craik FIM, McIntosh AR, Houle S, Tulving E. Functional neuroanatomy of

recall and recognition: A PET study in humans. Journal of Cognitive Neuroscience, 9(2):254-265, 1997.

40. Kapur S, Zipursky RB, Roy P, Jones C, Reed K, Remington G, Houle S: The relationship

between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study. Psychopharmacology, 131(2): 148-152, 1997.

41. Seeman P, Kapur S: Clozapine occupies high levels of dopamine D2 receptors. Life Sciences,

60 (12): 207-216 PL, 1997. 42. Goel V, Gold B, Kapur S, Houle S: The seats of reason: a localization study of deductive &

inductive reasoning using PET (O15) blood flow technique. NeuroReport, 8 (5): 1305-1310, 1997.

43. Kapur S, Jones C, DaSilva J, Wilson AA, Houle S: Reliability of a simple non-invasive method

for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. Nuclear Medicine Communications, 18: 395-399, 1997.

44. *Jennings JM, McIntosh AR, Kapur S, Tulving E, Houle S. Cognitive subtractions may not add

up: The interaction between semantic processing and response mode. Neuroimage, 5: 229-


239, 1997. 45. Kapur S, Zipursky RB, Remington G, Jones C, MacKay G, Houle S: PET evidence that

loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. American Journal of Psychiatry, 154: 1525-1529, 1997.

46. Kapur S: A new framework for investigating antipsychotic action in humans: Lessons from PET

Imaging. Molecular Psychiatry, 3:135-140, 1998. 47. Zipursky RB, Kapur S: New insights into schizophrenia from neuroimaging. Current Opinion in

Psychiatry, 11:33-37, 1998. 48. *Jennings JM, McIntosh AR, Kapur S: Mapping Neural Interactivity onto regional activity:

Analysis of semantic processing and response mode interactions. Neuroimage, 7: 244-254, 1998.

49. Goel V, Gold B, Kapur S & Houle S: Neuroanatomical Correlates of Human Reasoning.

Journal of Cognitive Neuroscience, 10 (3): 293-302, 1998. 50. *Jennings JM, McIntosh AR, Kapur S, Zipursky RB, Houle S: Functional network differences in

Schizophrenia: an rCBF study of Semantic Processing. NeuroReport, 9: 1697-1700, 1998. 51. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S: The 5-HT2 and

D2 receptor occupancy of Olanzapine in schizophrenia: A PET investigation. American Journal of Psychiatry, 155: 921-928, 1998.

52. Zipursky RB, Lambe EK, Kapur S, Mikulis DJ: Cerebral gray-matter volume deficits in first

episode psychosis. Archives of General Psychiatry, 55(6):540-546, 1998. 53. *Rajah N, Hussey D, Houle S, Kapur S, McIntosh AR: Task-independent effect of time on rCBF.

Neuroimage, 7(4): 314-325, 1998. 54. Craik FIM, Moroz TM, Moscovitch M, Stuss DT, Winocur G, Tulving E, Kapur S: In search of self

– a PET study of self-referential information. Psychological Science, 10(1):26-34; 1999. 55. Kapur S, Cho R, Jones C, McKay G, Zipursky RB: Is amoxapine an atypical antipsychotic? PET

investigation of its D2 and 5-HT2 occupancy. Biological Psychiatry, 45: 1217-1220, 1999. 56. *Lewis R, Kapur S, Zipursky RB, Jones C, DaSilva J, Wilson AA, Houle S: 5-HT2 receptors in

schizophrenia: a PET study using [18F]-setoperone in neuroleptic-naïve patients and normal controls. American Journal of Psychiatry, 156: 72-78, 1999.

57. Kapur S, Remington G, Zipursky RB: Comparison of the 5-HT2 and D2 receptor occupancy of

clozapine, risperidone and olanzapine in schizophrenia: clinical and theoretical Implications. American Journal of Psychiatry, 156: 286-293; 1999.

58. *Cho R, Kapur S, Du L, Hrdina PC: Relationship between central and peripheral serotonin 5HT2

receptors: a PET study in normal volunteers. Neuroscience Letters, 261: 139-142, 1999. 59. Remington G, Kapur S: D2 and 5-HT2 receptor effects on antipsychotics: Bridging basic and

clinical findings using PET. Journal of Clinical Psychiatry, 60 (Suppl. 10): 15-19, 1999. 60. Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, Wilson AA, Kennedy SH:


Prefrontal cortex 5-HT2 receptors in depression: an [18F] setoperone PET imaging study. American Journal of Psychiatry, 156: 1029-34, 1999.

61. *Meyer JH, Cho R, Kennedy S, Kapur S: The effects of single dose nefazodone and paroxetine

upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology, 144:279-281, 1999.

62. Kapur S, Zipursky RB, Jones C, Remington G, Houle S: The relationship between dopamine D2

occupancy, clinical response and side effects – a double blind PET study in first episode Schizophrenia. American Journal of Psychiatry, 157 (4): 514-520, 2000.

63. *Wadenberg ML, Sills T, Fletcher P, Kapur S: Antipsychotic-like effects of amoxapine without

catalepsy using the pre-pulse inhibition in rats. Biological Psychiatry, 47 (7): 670-676, 2000. 64. *Fitzgerald PB, Kapur S, Caligiuri MP, Jones C, Silvestri S, Remington G, Zipursky RB:

Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade. Neuropsychopharmacology, 22 (1):19-26, 2000.

65. *Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky RB: Predicting Haloperidol Occupancy

of Central Dopamine D2 Receptors from Plasma Levels. Psychopharmacology, 149 (1): 1-5, 2000.

66. *Iidaka T, Anderson N, Kapur S, Cabeza R, Craik FIM: The effect of divided attention on

encoding and retrieval in episodic memory revealed by Positron Emission Tomography. Journal of Cognitive Neuroscience, 12(2): 267-280, 2000.

67. Kapur S, Seeman P: Antipsychotics differ in how fast they come off the dopamine D2 receptors

– implications for atypical antipsychotics. Journal of Psychiatry and Neuroscience, 25 (2): 161-166, 2000.

68. Kapur S, Zipursky R, Jones C, Remington G, Seeman P: A PET study of Quetiapine in

Schizophrenia: A preliminary finding of antipsychotic effect with only transient dopamine D2 occupancy. Archives of General Psychiatry, 57 (6): 553-559, 2000.

69. Kapur S, Wadenberg ML, Remington G: Are animal studies of antipsychotics appropriately

dosed? Lessons from the bedside to the bench. Canadian Journal of Psychiatry, 45: 241-6, 2000.

70. Seeman P, Kapur S: Schizophrenia: more dopamine, more D2 receptors. Proceedings of the

National Academy of Sciences, 97: 7673-7675, 2000. [Editorial] 71. DeNil LF, Kroll RM, Kapur S, Houle, S: A positron emission tomography study of silent and oral

single word reading in stuttering and nonstuttering adults. Journal of Speech, Language and Hearing Research, 43: 1038-1053, 2000.

72. *Wadenberg M-L, Kapur S, Soliman A, Jones C, Vaccarino F: Dopamine D2 receptor occupancy

predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology, 150(4): 422-429, 2000.

73. Kapur S, Barsoum S, Seeman P: Dopamine D2 receptor blockade by haloperidol: 3H-


Raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology, 23(5): 595-598, 2000.

74. *Verhoeff NPLG, Meyer J, Kecojevic A, Hussey D, Lewis R, Tauscher J, Zipursky RB, Kapur S:

A voxel-by-voxel analysis of [18F] setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Research and Neuroimaging, 99: 123-135, 2000.

75. *Anderson N, Iidaka T, Cabeza R, Kapur S, McIntosh AR, Craik FIM: The effect of divided

attention on encoding and retrieval-related brain activity: A PET study of younger and older adults. Journal of Cognitive Neuroscience, 12(5): 775-792, 2000.

76. Kapur S, Remington G: Atypical antipsychotics. Patients value the lower incidence of

extrapyramidial side effects. British Medical Journal, 321(7273):1360-1361, 2000. [Editorial] 77. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky

RB, Wilson AA, Christensen BK, Seeman P: Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 152(2):174-80, 2000.

78. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg

HS, Kennedy SH: The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study. American Journal of Psychiatry, 158(1):78-85, 2001.

79. Kapur S, Remington G. Atypical Antipsychotics: New Directions and New Challenges in the

Treatment of Schizophrenia. Annual Review of Medicine, 52(1): 503-517, 2001. 80. Kapur S, Seeman P: Fast dissociation from the dopamine D2 receptors explains atypical

antipsychotic action - a new hypothesis. American Journal of Psychiatry, 158: 360-369, 2001. 81. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R: Increased Dopamine D (2) Receptor

Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. American Journal of Psychiatry, 158(2): 311-314, 2001.

82. *Verhoeff NPLG, Kapur S: Neuroimaging and antipsychotics. Journal of Pharmacy Practice,

14(4): 332-340, 2001. 83. *Tauscher J, Verhoeff NPLG, Christensen B, Hussey D, Meyer JH, Kecojevic A, Javanmard M,

Kasper S, Kapur S: Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology, 24:522-30, 2001.

84. *Verhoeff NPLG, Kapur S, Hussey D, Lee M, Christensen B, Papatheodorou G, Zipursky RB: A

simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology, 25: 213-223, 2001.

85. Remington G, Kapur S: SB-277011 GlaxoSmithKline – a highly selective D3 antagonist. Current

Opinion in Investigational Drugs, 2 (7): 946-949, 2001.


86. *Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S: Inverse

relationship between serotonin 5-HT1A receptor binding potential and trait anxiety - a [11C]WAY-100635 PET investigation in healthy volunteers. American Journal of Psychiatry, 158: 1326-1328, 2001.

87. *Sa D, Kapur S, Lang AE: Amoxapine shows an antipsychotic effect but worsens motor function

in parkinson’s disease patients with psychosis. Clinical Neuropharmacology, 24 (4): 242-244, 2001.

88. Kapur S, Barlow K, VanderSpek SC, Javanmard M, Nobrega JN: Drug-induced receptor

occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychopharmacology, 157(2): 168-71, 2001.

89. Kapur S: Neuroimaging and drug development: an algorithm for decision making. Journal of

Clinical Pharmacology, Suppl.: 64S-71S, 2001. 90. *Tauscher J, Kapur S: Choosing the right dose of antipsychotics in schizophrenia – lessons

from neuroimaging studies. CNS Drugs, 15(9): 671-678, 2001. 91. *Wadenberg M-L, Soliman A, VanderSpek SC, Kapur S: Dopamine D2 receptor occupancy is a

common mechanism underlying animal modes of antipsychotics and their clinical effects. Neuropyschopharmacology, 25: 633-641, 2001.

92. Kapur S, Remington G: Dopamine D2 receptors and their role in atypical antipsychotic action:

Still necessary and may even be sufficient. Biological Psychiatry, 50: 873-881, 2001. 93. *Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S: Evidence for

Impaired Cortical Inhibition in Schizophrenia Using Transcranial Magnetic Stimulation. Archives of General Psychiatry, 59: 347-354, 2002.

94. *Turrone P, Kapur S, Seeman MV, Flint A: Atypical antipsychotics also give rise to prolactin

elevation. American Journal of Psychiatry, 159: 133-135, 2002. 95. Suhara T, Okauchi T, Sudo Y, Takano A, Kawabe K, Maeda J, Kapur S: Clozapine can induce

high dopamine D(2) receptor occupancy in vivo. Psychopharmacology, 160: 107-112, 2002. 96. *Tauscher J, Kapur S, Verhoeff NPLG, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S,

Wilson AA, Houle S, Kasper S, Zipursky RB: Brain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635. Archives of General Psychiatry, 59(6): 514-520, 2002.

97. *Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S: Significant dissociation of brain and

plasma kinetics with antipsychotics. Molecular Psychiatry, 7: 317-321, 2002. 98. *Verhoeff NPLG, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur

S: Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans. Molecular Psychiatry: 7: 322-328, 2002.


99. *Ko F, Seeman P, Sun WS, Kapur S: Dopamine D2 receptors internalize in their low-affinity state. NeuroReport, 13(8):1017-20, 2002.

100. Kapur S, McClelland RA, VanderSpek SC, Wadenberg M-L, Baker G, Nobrega J, Zipursky RB,

Seeman P: Increasing D2 affinity results in the loss of clozapine’s ‘atypical’ antipsychotic action. NeuroReport, 13(6): 831-835, 2002.

101. Kapur S, Seeman P: NMDA receptor antagonists ketamine and PCP have direct effects on the

dopamine D2 and serotonin 5-HT2 receptors – implications for models of schizophrenia. Molecular Psychiatry, 7(8): 837-844, 2002.

102. *Tauscher-Wisniewski S, Kapur S , Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G,

Epstein I, Christensen BK, Zipursky RB: Quetiapine - an effective antipsychotic in first episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Journal of Clinical Psychiatry, 63(11): 992-997, 2002.

103. Seeman P, Tallerico T, Ko F, Tenn C, Kapur S: Amphetamine-sensitized animals show a

marked increase in dopamine D2 receptors occupied by endogenous dopamine – even in the absence of acute challenges. Synapse, 46(4): 235-239, 2002.

104. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS: The differential effects

of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. Journal of Pharmacology and Experimental Therapeutics, 302:1129-34, 2002.

105. Apiquian R, Ulloa E, Fresan A, Loyzaga C, Nicolini H, Kapur S: Amoxapine shows atypical

antipsychotic effects in patients with schizophrenia: results from a prospective open label study. Schizophrenia Research, 59(1), 35-39, 2003.

106. Verhoeff NPLG, Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L, Rui Q,

Zipursky RB, Kapur S: Effects of catecholamine depletion on D2 receptor binding, mood and attentiveness in humans: a replication study. Pharmacology Biochemistry and Behaviour, 74: 425-432. 2003.

107. *Turrone P, Remington G, Kapur S, Nobrega JN: The Relationship between dopamine D2

receptor occupancy and the vacuous chewing movement (VCM) syndrome in rats. Psychopharmacology, 165 (2), 166-171, 2003.

108. Kapur S: Psychosis as a state of aberrant salience: a framework linking biology,

phenomenology and pharmacology in Schizophrenia. American Journal of Psychiatry, 160(1): 13-23, 2003.

109. *Sun W, Ginovart N, Ko F, Seeman P, Kapur S: In vivo evidence for dopamine-mediated

internalization of D2-receptors following amphetamine: Differential findings with [3H]raclopride versus [3H]spiperone. Molecular Pharmacology, 63(2): 456-462, 2003.

110. Kapur S, VanderSpek SC, Brownlee BA, Nobrega, JN: Antipsychotic dosing in preclinical

models is often unrepresentative of the clinical condition – a suggested solution based on in vivo occupancy. Journal of Pharmacology and Experimental Therapeutics, 305(2):625-631,2003.


111. *Kiang M, Daskalakis ZJ, Christensen BK, Remington G, Kapur S: Actigraphic measurement of

the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. Journal of Psychiatry and Neuroscience, 28(4): 293-299, 2003.

112. Verhoeff NPLG, Hussey D, Lee M, Christensen BK, Papatheodorou G, Zipursky RB, Kapur S:

Effects of catecholamine depletion on D2 receptor binding and mood in healthy humans. Brain and Cognition, 51: 200-202, 2003.

113. *Smith A, Becker S, Kapur S: From dopamine to psychosis: A computational approach.

Knowledge-Based Intelligent Information and Engineering Systems, Pt 2, Proceedings. 2774(6):1115-1121, 2003.

114. *Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action:

a hypothesis tested and rejected. Archives of General Psychiatry, 60(12):1228-35, 2003. 115. *Tenn CC, Fletcher PJ, Kapur S: Amphetamine-sensitized animals show a sensorimotor gating

and neurochemical abnormality similar to that of schizophrenia. Schizophrenia Research, 15: 64(2-3):103-14, 2003.

116. Abosch A, Kapur S, Lang AE, Hussey D, Sime E, Miyasaki J, Houle S, Lozano AM: Stimulation

of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery, 53(5): 1095-102; discussion 1102-5, 2003.

117. *Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S: Effect of Antipsychotics On Cortical Inhibition Using Transcranial Magnetic Stimulation. Psychopharmacology (Berl), 170(3): 255-62, 2003.

118. *Kiang M, Christensen BK, Remington G, Kapur S. Apathy in schizophrenia: clinical correlates

and association with functional outcome. Schizophrenia Research, 63(1-2): 79-88, 2003. 119. Seeman P, Kapur S: Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked

receptors. Synapse, 50(1): 35-40, 2003. 120. *Turrone P, Remington G, Kapur S: Nobrega JN. Differential effects of within-day continuous vs.

transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology, 28(8): 1433-9, 2003.

121. *Kiang M, Daskalakis ZJ, Christensen BK, Remington G, Kapur S: Actigraphic measurement of

the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. Journal of Psychiatry and Neuroscience, 28(4): 293-299, 2003.

122. *Jensen J, McIntosh AR, Crawley AP, Mikulis DJ, Remington G, Kapur S: Direct Activation of

the Ventral Striatum in anticipation of Aversive Stimuli. Neuron, 40: 1251-1257, 2003. 123. Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2

receptors. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27: 1081-1090, 2003.


124. Cardenas L, Houle S, Kapur S, Busto UE: Oral D-amphetamine causes prolonged displacement

of [11C]raclopride as measured by PET. Synapse, 51(1): 27-31, 2004. 125. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G: A PET

study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. American Journal of Psychiatry, 191(5): 818-825, 2004.

126. Mamo D, Remington G, Nobrega J, Hussey D, Chirakal R, Wilson AA, Baker G, Houle S,

Kapur S: Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. Synapse, 52(2): 153-62. 2004

127. Ginovart N, Sun W, Wilson AA, Houle S, Kapur S: Quantitative validation of an intracerebral

beta-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats. Synapse, 52(2): 89-99, 2004.

128. Ginovart N, Wilson AA, Houle S, Kapur S: Amphetamine pretreatment induces a change in

both D2-Receptor density and apparent affinity: a [11C] raclopride positron emission tomography study in cats. Biological Psychiatry, 55(12): 1188-1194, 2004.

129. *Smith A, Li M, Becker S, Kapur S: A model of antipsychotic action in conditioned avoidance: a

computational approach. Neuropsychopharmacology, 29(6): 1040-1049, 2004 130. Kapur S: How antipsychotics become anti-“psychotic”—from dopamine to salience to

psychosis. Trends in Pharmacological Sciences, 25 (8): 402-406, 2004. 131. *Li M, Davidson P, Budin R, Kapur S, Fleming AS: Effects of typical and atypical antipsychotic

drugs on maternal behavior in postpartum female rats. Schizophrenia Research, 70(1): 69-80, 2004.

132. *Li M, Parkes J, Fletcher PJ, Kapur S: Evaluation of the motor initiation hypothesis of APD-

induced conditioned avoidance decreases. Pharmacology Biochemistry and Behavior, 78(4): 811-819, 2004

133. *Tauscher J, Hussain T, Agid O, Verhoeff NPLG, Wilson AA, Houle S, Remington G, Zipursky

RB, Kapur S: Equivalent Occupancy of Dopamine D2 and D2 Receptors with Clozapine: Differentiation from Other Atypical Antipsychotics. American Journal of Psychiatry, 161 (9): 1620-1625, 2004.

134. Fitzgerald PB, Filia S, De Castella A, McBain N, Kapur S, Kulkarni J: Amoxapine in

schizophrenia: a negative double-blind controlled trial. Journal of Clinical Psychopharmacology, 24(4): 448-50, 2004.

135. Takano A, Suhara T, Maeda J, Ando K, Okauchi T, Obayashi S, Nakayama T, Kapur S:

Relation between cortical dopamine D(2) receptor occupancy and suppression of conditioned avoidance response in non-human primate. Psychiatry and Clinical Neurosciences, 58(3):330-2, 2004.


136. Mamo D, Sedman E, Tillner J, Sellers EM, Romach MK, Kapur S. EMD 281014, a specific and

potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology, 175(3):382-8, 2004.

137. *Turrone P, Remington G, Kapur S, Nobrega JN: Continuous but not intermittent olanzapine

infusion induces vacuous chewing movements in rats. Biological Psychiatry, 57(4):406-11, 2005.

138. *Tenn CC, Fletcher PJ, Kapur S: A putative animal model of the "prodromal" state of

schizophrenia. Biological Psychiatry, 57(6):586-593, 2005. 139. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B: Evidence for onset of

antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry, 162(5):939-46, 2005.

140. * Smith AJ, Becker S, Kapur S: A computational model of the functional role of the ventral-

striatal D2 receptor in the expression of previously acquired behaviors. Neural Computation,17(2):361-95, 2005.

141. *Tenn CC, Kapur S, Fletcher PJ: Sensitization to amphetamine, but not phencyclidine, disrupts

prepulse inhibition and latent inhibition. Psychopharmacology, 180(2):366-76, 2005. 142. Kippin TE, Kapur S, v`an der Kooy D: Dopamine specifically inhibits forebrain neural stem cell

proliferation, suggesting a novel effect of antipsychotic drugs. Journal of Neuroscience, 25(24):5815-23, 2005.

143. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P,

Ginovart N: Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9 -ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. Journal Medicinal Chemistry, 48(12):4153-60, 2005.

144. * Mizrahi R, Bagby RM, Zipursky RB, Kapur S: How antipsychotics work: The patients'

perspective. Proggress in Neuro-Psychopharmacol and Biological Psychiatry, 29(5):859-64, 2005.

145. *Li M, Budin R, Fleming AS, Kapur S: Effects of chronic typical and atypical antipsychotic drug

treatment on maternal behavior in rats. Schizophrenia Research, 75(2-3):325-36, 2005. 146. *Li M, Budin R, Fleming AS, Kapur S: Effects of novel antipsychotics, amisulpiride and

aripiprazole, on maternal behavior in rats. Psychopharmacology,181(3):600-10, 2005. 147. Kapur S, Mizrahi R, Li M: From dopamine to salience to psychosis-linking biology,

pharmacology and phenomenology of psychosis. Schizophrenia Research, 79(1):59-68, 2005. 148. *Natesan S, Vanderspek S, Nobrega JN, McClelland RA, Kapur S: Contrasting loxapine to its

isomer isoloxapine-the critical role of in vivo D(2) blockade in determining atypicality.


Schizophrenia Research, 77(2-3):189-99, 2005. 149. Zipursky RB, Christensen BK, Daskalakis Z, Epstein I, Roy P, Furimsky I, Sanger T, Kapur S:

Treatment response to olanzapine and haloperidol and its association with dopamine D2 receptor occupancy in first-episode psychosis. Canadian Journal of Psychiatry, 50(8):462-9, 2005.

150. Fletcher PJ , Tenn CC, Rizos Z, Lovic V, Kapur S: Sensitization to amphetamine, but not PCP,

impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology, 183(2):190-200, 2005.

151. Remington G, Kapur S: Remission: what's in a name? American Journal of Psychiatry,

162(12):2393-4, 2005. 152. Remington G, Seeman P, Shammi C, Mann S, Kapur S: "Extended" antipsychotic dosing:

rationale and pilot data. Journal of Clinical Psychopharmacology. 25(6):611-3, 2005. 153. *Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S: Dissociation between In Vivo

Occupancy and Functional Antagonism of Dopamine D(2) Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models. Neuropsychopharmacology, 31(9):1854-63, 2006.

154. *Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA: High-Affinity States

of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [(11)C]-(+)-PHNO. Biological Psychiatry, 59(5):389-94, 2006.

155. Kapur S, Agid O, Mizrahi R, Li M: How antipsychotics work - from receptors to reality. NeuroRx,

3(1):10-21, 2006. 156. Remington GA, Mamo D, Labelle A, Reiss J, Shammi CM, Mannaert E, Mann S, Kapur S: PET

study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. American Journal of Psychiatry, 163(3):396-40, 2006.

157. *Agid O, Seeman P, Kapur S: The "delayed onset" of antipsychotic action--an idea whose time

has come and gone. Journal of Psychiatry & Neuroscience, 31(2):93-100, 2006. 158. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S,

Wilson AA: Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. Journal of Neurochemistry, 97(4):1089-103, 2006.

159. *Smith AJ, Li M, Becker S, Kapur S: Dopamine, prediction error and associative learning: a

model-based account. Network, 17(1):61-84, 2006. 160. *Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S: The

Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat. Journal of Pharmacology and Experimental Therapeutics, 318(2):810-8, 2006.


161. Galineau L, Wilson AA, Garcia A, Houle S, Kapur S, Ginovart N: In vivo characterization of the

pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse, 60(2):172-83, 2006.

162. Seeman P, Wilson AA, Gmeiner P, Kapur S: Dopamine D2 and D3 receptors in human

putamen, caudate nucleus, and globus pallidus. Synapse, 60(3):205-11, 2006. 163. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, Tetsuya S, Houle S, Kapur S: An

automated method for the extraction of regional data from PET images. Psychiatry Research. Neuroimaging, 147(1):79-89, 2006.

164. *Mizrahi R, Kiang M, Mamo DC, Arenovich T, Bagby RM, Zipursky RB, Kapur S: The selective

effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophrenia Research, 88(1-3):111-8, 2006.

165. Chew ML, Mulsant BH, Pollok BJ, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S,

Gharabawi G: A model of anticholinergic activity of atypical antipsychotic medications. Schizophrena Research, 88(1-3):63-72, 2006.

166. *Li M, Fletcher PJ, Kapur S: Time Course of the Antipsychotic Effect and the Underlying

Behavioral Mechanisms. Neuropsychopharmacology, 32(2):263-72, 2007. 167. *Jensen J, Smith AJ, Willeit M, Crawley AP, Mikulis DJ, Vitcu I, Kapur S: Separate brain regions

code for salience vs. valence during reward prediction in humans. Human Brain Mapping, 28(4):294-302, 2007.

168. *Benaliouad F, Kapur S, Rompre PP: Blockade of 5-HT2a Receptors Reduces Haloperidol-

Induced Attenuation of Reward. Neuropsychopharmacology, 32(3):551-61, 2007. 169. Fletcher PJ, Tenn CC, Sinyard J, Rizos Z, Kapur S: A Sensitizing Regimen of Amphetamine

Impairs Visual Attention in the 5-Choice Serial Reaction Time Test: Reversal by a D1 Receptor Agonist Injected into the Medial Prefrontal Cortex. Neuropsychopharmacology, 32(5):1122-32, 2007.

170. *Feathersone RE, Rizos Z, Nobrega Jn, Kapur S, Fletcher PJ: Gestational Methylazoxymethanol

Acetate Treatment Impairs Select Cognitive Functions: Parallels to Schizophrenia. Neuropsychopharmacology, 32(2):483-92, 2007.

171. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA: Positron

emission tomography quantification of [(11)C]-(+)-PHNO binding in the human brain. Journal of Cerebral Blood Flow & Metabolism, 27(4):857-71, 2007.

172. Agid O, Mamo DC, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S: Striatal versus

extrastriatal dopamine D2 receptors in antipsychotic response – a double blind PET study in schizophrenia. Neuropsychopharmacology, 32(6):1209-15, 2007.

173. *Mizrahi R, Korostil M, Starkstein SE, Zipursky RB, Kapur S: The effect of antipsychotic

treatment on Theory of Mind. Psychological Medicine, 37(4):595-601, 2007.


174. *Natesan S, Reckless GE, Barlow KBL, Nobrega JN, Kapur S: Evaluation of N-

Desmethylclozapine as a Potential Antipsychotic - Preclinical Studies. Neuropsychopharmacology, 32(7):1540-9, 2007.

175. *Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, Kapur S: Adverse subjective

experience with antipsychotics and its relationship to striatal and extra-striatal D2 receptors - a PET study in schizophrenia. American Journal of Psychiatry, 164(4):630-7, 2007.

176. *Menon M, Jensen J, Vitcu I, Graff-Guerrero A, Crawley AP, Smith MA, Kapur S: Temporal

difference modeling of the BOLD response during aversive conditioning in humans: Effects of dopaminergic modulation. Biological Psychiatry, 62(7):765-72, 2007.

177. Odontiadis J, MacKenzie EM, Natesan S, Mamo D, Kapur S, Baker GB: Quantification of

stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescent end-point detection. Journal of Chromatography, 850(1-2):544-7, 2007.

178. *Smith AJ, Li M, Becker S, Kapur S: Linking Animal Models of Psychosis to Computational

Models of Dopamine Function. Neuropsychopharmacology, 32(1):54-66, 2007. 179. Seeman P, McCormick PN, Kapur S: Increased dopamine D2(High) receptors in amphetamine-

sensitized rats, measured by the agonist [(3)H](+)PHNO. Synapse, 61(5):263-7, 2007. 180. *Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: "Breakthrough" dopamine

supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. Journal of Neuroscience, 27(11):2979-86, 2007.

181. Lanctôt KL, Hussey DF, Herrmann N, Rusjan PM, Black SE, Wilson AA, Houle S, Kozloff N,

Verhoeff NPLG, Kapur S: A PET study of serotonin 5-HT1A receptor binding potential in Alzheimer’s disease. Am J Geriatr Psychiatry, 15(10):888-98, 2007.

182. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S: Differential effects of

aripiprazole on D(2), 5-HT(2), and 5-HT(1ª) receptor occupancy in patients with schizophrenia: a triple tracer PET study. American Journal of Psychiatry, 164(9):1411-7, 2007

183. Chaudhry IB, Husain N, Khan S, Badshah S, Deakin B, Kapur S: Amoxapine as an antipsychotic:

comparative study versus haloperidol. Journal of Clinical Psychopharmacolgy, 27(6):575-81, 2007.

184. Featherstone RE, Kapur S, Fletcher PJ: The amphetamine-induced sensitized state as a model

of schizophrenia. Progress in Neuropsychopharmacol and Biological Psychiatry, 31(8):1556-71, 2007.

185. *Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB: Early use of clozapine for poorly

responding first-episode psychosis. J Clin Psychopharmacol, 27(4):369-73, 2007. 186. * Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S: First

human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology, 33(2):279-


89, 2008. 187. * Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, Mann SW, Remington G:

Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry, 69(8):1281-6 2008.

188. *Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S: Less is more:

antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry, 64(2):145-52, 2008.

189. *Natesan S, Reckless GE, Barlow KB, Odontiadis J, Nobrega JN, Baker GB, George SR, Mamo

D, Kapur S: The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology, 199(2):275-89, 2008.

190. *Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S: Amisulpride the 'atypical' atypical

antipsychotic--comparison to haloperidol, risperidone and clozapine. Schizophrenia Research, 105(1-3):224-35 2008.

191. *Mizrahi R, Addington J, Remington G, Kapur S: Attribution style as a factor in psychosis and

symptom resolution. Schizophrenia Research, 104(1-3):220-7, 2008. 192. * Menon M, Mizrahi R, Kapur S: 'Jumping to conclusions' and delusions in psychosis:

relationship and response to treatment. Schizophrenia Research, 98(1-3):225-31, 2008. 193. Mead A, Li M, Kapur S: Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two

conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav, 90(4):551-62, 2008.

194. *McCormick PN, Kapur S, Seeman P, Wilson AA: Dopamine D2 receptor radiotracers

[(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nuclear Medicine and Biology, 35(1):11-7, 2008

195. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S: Quetiapine

extended-release versus immediate-release formulation: a positron emission tomography study. Journal of Clinical Psychiatry, 69(1):81-6, 2008

196. Mamo D, Kapur S, Keshavan M, Laruelle M, Taylor CC, Kothare PA, Barsoum P, McDonnell D:

D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology, 33(2):298-304, 2008.

197. *Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S: The

formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology, 33(3):473-9, 2008.

198. Howes OD, McGuire PK, Kapur S: Understanding pathophysiology is crucial in linking clinical

staging to targeted thera-peutics. World Psychiatry,7(3):162-3, 2008. 199. *Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P,


Wilson AA, Kapur S: Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Human Brain Mapping, 29(4):400-10, 2008.

200. *Featherstone RE, Rizos Z, Kapur S, Fletcher PJ: A sensitizing regimen of amphetamine that

disrupts attentional set-shifting does not disrupt working or long-term memory. Behavioral Brain Research, 189(1):170-9, 2008.

201. Arranz MJ, Kapur S: Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Schizophrenia Bulletin, 34(6):1130-44, 2008. 202. Agid O, Kapur S, Warrington L, Loebel A, Siu C: Early onset of antipsychotic response in the

treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research, 102(1-3):241-8, 2008.

203. Agid O, Kapur S, Remington G: Emerging drugs for schizophrenia. Expert Opin Emerg Drugs,

13(3):479-95, 2008. 204. Schizophrenia aetiology: do gene-environment interactions hold the key? [collaborative author as

part of the European Network of Schizophrenia Networks for the Study of Gene-Environment Interactions] Schizophrenia Research, 102(1-3):21-6, 2008.

205. *Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S: Increased antipsychotic sensitivity in

elderly patients: evidence and mechanisms. Journal of Clinical Psychiatry, 70(3):397-405, 2009.

206. *Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC: Sensitivity of older

patients to antipsychotic motor side effects: a PET study examining potential mechanisms. American Journal of Geriatric Psychiatry, 17(3):255-63, 2009.

207. *Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM: The

acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 39(10):1607-16, 2009.

208. * Mizrahi R, Mamo D, Rusjan P, Graff A, Houle S, Kapur S: The relationship between subjective

well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. International Journal Neuropsychopharmacology, 12(5):715-21, 2009.

209. *Jensen J, Kapur S: Salience and psychosis: moving from theory to practise [editorial].

Psychological Medicine, 39(2):197-8, 2009. 210. Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III--the final common

pathway. Schizophrenia Bulletin, 35(3):549-62, 2009. 211. *Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R,

Kapur S: The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology, 34(4):1078-86, 2009.


212. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S: D2-receptor upregulation is dependent

upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology, 34(3):662-71, 2009.

213. Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA: Dopaminergic activity in

depressed smokers: A positron emission tomography study. Synapse, 63(8):681-689, 2009. 214. *Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y,

Wilson AA, Kapur S, Kish SJ: Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain, 132(5):1366-75, 2009.

215. *Benaliouad F, Kapur S, Natesan S, Rompre PP: Effects of the dopamine stabilizer, OSU-6162,

on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. European Neuropsychopharmacology, 19(6):416-30, 2009.

216. *Featherstone RE, Burton CL, Coppa-Hopman R, Rizos Z, Sinyard J, Kapur S, Fletcher PJ:

Gestational treatment with Methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. Pharmacology Biochemistry and Behaviour, 93(4):382-90, 2009.

217. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S,

Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J: Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology, 19(7):520-32, 2009.

218. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston

JP: Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J, Epub 19May 2009.

219. *Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S,

Wilson AA, Kapur S: The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry, 66(6):606-15, 2009.

220. *Winton-Brown TT, Kapur S: Neuroimaging of schizophrenia: what it reveals about the disease

and what it tells us about a patient. Ann Acad Med Singapore, 38(5):433-3, 2009. 221. *Sparshatt A, Taylor D, Patel MX, Kapur S: Amisulpride - dose, plasma concentration, occupancy

and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand, Epub1 July 2009.

222. *McCormick PN, Kapur S, Reckless G, Wilson AA: Ex vivo [11C]-(+)-PHNO binding is

unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. Synapse, 63(11):998-1009, 2009.

223. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S: Mechanisms underlying

psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des, 15(22):2550-9, 2009.


224. Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ: Rapid antipsychotic response with

ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res, Epub 20 Aug 2009.

225. van Os J, Kapur S: Schizophrenia. Lancet, 374(9690):635-45, 2009. 226. Appel L, Geffen Y, Heurling K, Eriksson C, Antoni G, Kapur S: BL-1020, a novel antipsychotic

candidate with GABA-enhancing effects: D(2) receptor occupancy study in humans. Eur Neuropsychopharmacol, Epub 28 Aug 2009.

Major Reports Medical Research: What’s it worth? Estimating the economic benefits from medical research in the UK. London: UK Evaluation Forum; 2008

Martin Buxton, Steve Hanney, Steve Morris, Leonie Sundmacher, Jorge Mestre-Ferrandiz, Martina Garau, Jon Sussex, Jonathan Grant, Sharif Ismail, Eddy Nason, Steve Wooding, Shitij Kapur Letters to the Editor 1. Al-Jeshi A, Jeffries JL, Kapur S. Loxapine: An enigma. Can J Psychiatry. 41(2): 131-132, 1996. 2. Kapur S, Zipursky RB, Jones C, Wilson AA, DaSilva JD, Houle S. Cyproheptadine: A potent in vivo

5-HT2 antagonist. American Journal of Psychiatry. 154 (6): 884, 1997. 3. Remington G, Kapur S, Zipursky RB. The relationship between risperidone plasma levels and

dopamine D2 occupancy: A PET study. Journal of Clinical Psychopharmacology. 18(1):82-83, 1998. 4. Kapur S, Remington G, Zipursky RB. Does loxapine plus cyproheptadine make an atypical

antipsychotic: PET analysis of its D2 and 5-HT2 receptor occupancy. Archives of General Psychiatry 55: 666-667, 1998.

5. Remington G, Kapur S, Zipursky RB. APA Practice guidelines for Schizophrenia: Risperidone

equivalents. American Journal of Psychiatry, 155 (9): 1301-1302, 1998. 6. Zipursky RB, Kapur S. Structural brain changes in Schizophrenia. Archives of General Psychiatry

56: 195-196, 1999. 7. Remington G, Chong SA, Kapur S: Distinguishing change in primary and secondary negative

symptoms [letter]. Am J Psychiatry, 156:974-975, 1999. 8. Kapur S and Seeman P. Ketamine has equal affinity for NMDA receptors and the high-affinity

state of the dopamine D2 receptor. Biol Psychiatry, 49: 954-7, 2001. 9. Kapur S and Seeman P: Atypical antipsychotics, cortical D(2) receptors and sensitivity to

endogenous dopamine. Br J Psychiatry 180:465-6, 2002. 10. Remington G, Kapur S: Review: amisulpride is effective and safe for schizophrenia. Evid Based

Ment Health 5:85, 2002.


11. Remington G, Kapur S: Remission: what's in a name? American Journal of Psychiatry.

162(12):2393-4; 2005. Articles Online Kapur S. Polypharmacy-in-a-Pill: A Scientific Advance or Are We Making a Virtue of Our Necessities? Medscape. [http://www.medscape.com/Medscape/psychiatry/journal/public/archive/2001/toc-0602.html] Book Dopamine in the pathophysiology and therapeutics of schizophrenia: new findings, new directions. Editors: S Kapur and Y Lecrubier. Martin Dunitz Publishers. London. 2003. Maudsley Prescribing Guidelines, 10th Edition. Authors and Editors: Taylor D, Paton C and Kapur S. Informa Healthcare, UK, 2009. Book Chapters 1. Kapur S, Keshavan MS: Psychotropic drug misuse. In: Drug Induced Dysfunction in Psychiatry.

MS Keshavan et al. Eds. Hemisphere Publications. 1992. 2. Kapur S, Kambhampatti RK: Adverse drug interactions. In: Drug Induced Dysfunction in

Psychiatry. MS Keshavan et al. Eds. Hemisphere Publications. 1992. 3. Kapur S, Mann JJ: Neurobiology of ECT. human studies. In: ECT from Research to Clinical

Practice, CE Coffey Ed. APA Press. 1993.

4. Houle S, Kapur S, Hussey D, Jones C, DaSilva J, Wilson AA. Measurement of [11C]-Raclopride using a bolus plus infusion protocol. In: Quantification of Brain Function using PET. Eds: R Myers, VJ Cunningham, DL Bailey, T Jones. Academic Press. San Diego. 1996. pp 262-265.

5. Kapur S, Seeman P: Antipsychotics. In: The Principles of Medical Pharmacology. H Kalant and

WHE Roschlau Eds. BC Decker Inc. Toronto. 1998. 6. Hussey D, DaSilva J, Greenwald E, Cheung K, Kapur S, Wilson AA, Houle S. Statistical Power

Analysis of in vivo studies in rat brain using PET radiotracers. In: Quantitative Functional Brain Imaging with Positron Emission Tomography. Academic Press. San Diego. 1998. pp 273-277.

7. Fitzgerald P, Kapur S, Seeman P. Neuroreceptor studies in the elderly: Potential for understanding

antipsychotic effects. In: Late-Onset Schizophrenia. Eds: Howard R, Rabins PV, Castle DJ. Wrightson Biomedical Publishing Ltd. Philadelphia. 1999. pp 205-216.


8. Grady C and Kapur S. The use of neuroimaging in neurorehabilitative research. In: Cognitive

Neurorehabilitation. Eds. D Stuss, I Robertson. Cambridge University Press. 1999. 9. Seeman P and Kapur S. Olanzapine binding to dopamine receptors in vitro and in vivo. In:

Olanzapine – a novel antipsychotic. Eds. Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G. Lippincott Williams and Wilkins. 2000. Pp 3-25.

10. Kapur S. Receptor occupancy by antipsychotics – Concepts and Findings. In: Neurotransmitter

Receptors in the Actions of Antipsychotic Medicatations. Ed. M Lidow. CRC Press, Boca Raton, USA. Pp 163-176. 2000.

11. Remington G, Kapur S, Zipursky RB. Pharmacotherapy of First Episode Psychosis. In Early

Intervention in Psychotic Disorders. Ed. T. Miller. Kluwer Scientific, Netherlands. Pp 167-180, 2001. 12. Seeman P and Kapur S. Dopamine receptor basis of psychosis. In: Current Issues in the

Psychopharmacology of Schizophrenia. Eds. Breier A, Tran PV, Herrera J, Bymaster F, Tollefson G. Lippincott Williams and Wilkins. Pp 3-25. 2001

13. Vidailihet P, Christensen B, Danion J-M, Kapur S. Episoidic memory impairment in schizophrenia:

A view from cognitive psychopathology. In: Perspectives on Human Memory and Cognitive Aging. Eds. Naveh-Benjamin M, Moscovitch M, Roediger HL. Psychology Press. Pp 348-362. 2001

14. Verhoeff NPLG, Kapur S. Imaging antipsychotic action at dopamine receptors. In:Dopamine

Receptors and Transporters. 2nd Edition. Eds. Sidhu A, Vernier P, Laruelle M. Marcel Dekker, Inc., New York 2003: 683-703.

15. Kapur S. Modulation of dopamine D2 receptors as a basis of antipsychotic effect – still necessary

and may even be sufficient. In: Dopamine in the pathophysiology and therapeutics of schizophrenia: new findings, new directions. Eds: S Kapur and Y Lecrubier. Martin Dunitz Publishers. London. In Editorial Revision 2003.

Book Reviews 1. Kapur S. Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE and Kupfer

DJ. 1995. Raven Press. Review published in Journal of Psychosomatic Research. 2. Kapur S. Memory Distortion: How Minds, Brains, and Societies Reconstruct the Past, edited by

Daniel Schacter and Joseph Coyle. 1995. Harvard University Press. Review published in the American Journal of Psychiatry.

PATENTS 1. Atypical antipsychotics having low affinity for the dopamine D2 receptor. S Kapur and R McClleland

(assigned to Neuromolecular Inc.). US Patent 6,890,919 B2. Issued May 10, 2005.


SELECTED PRESENTATIONS AND SPECIAL LECTURES

(ONLY FIRST AUTHORED POSTERS/PRESENTATIONS TRACKED) 1. Imaging the functional anatomy of the dopaminergic pathways. Conference on ‘Dopamine in Neuropsychiatric Disorders’, Upjohn Pharmaceuticals. Kalamazoo, USA, 1994. 2. Role of the left prefrontal cortex in verbal tasks: semantic processing or willed action? Society of

Nuclear Medicine 41st Annual Meeting, Orlando, 1994. Poster. Published in Journal of Nuclear Medicine, 35: 201P.

3. Statistical power analysis of PET cognitive studies using 15O-water. Society of Nuclear Medicine

41st Annual Meeting, Orlando, 1994. Poster. Published in Journal of Nuclear Medicine, 35: 182P. 4. A PET study of functional dissociation of episodic and semantic memory. Annual Meeting of the

Canadian Association for Nuclear Medicine, Banff, 1994. Oral Presentation. 5. Functional effects of dopaminergic stimulation measured using PET: an in vivo tool to study the

dopaminergic system. Annual Meeting of Clinical Research Society, Toronto. 1994. Oral Presentataion.

6. Functional anatomy of the dopaminergic system: PET study in humans. XIXth C.I.N.P Congress.

Washington D.C. 1994. Oral Presentation. Published in Neuropsychopharmacology, 10 (Suppl. 2): 17S.

7. Dissociation of the functional pathways involved in spatial as opposed to object long term memory.

XIXth C.I.N.P Congress. Washington D.C. 1994. Oral Presentation. Published in Neuropsychopharmacology, 10 (Suppl. 2): 29S

8. Localization of the functional effects of apomorphine - a PET study in humans. Annual Meeting of

the Society for Biological Psychiatry. Philadelphia. 1994. Published in Biological Psychiatry, 35: 682.

9. The role on functional neuroimaging in the development of new antipsychotics. Conference on

“Treatment Challenges in Schizophrenia”. University of Pittsburgh, USA, 1995. 10. The functional anatomy of the dopaminergic system - apomorphine challenge with PET. Invited

speaker. Symposium on “Neuroimaging in Neuropsychiatric Disorders”. Annual Meeting of the Canadian College of Neuropsychopharmacology, Vancouver, Canada,1995.

11. Neural correlates of encoding and retrieval in human memory: PET findings. Invited speaker at the

symposium “Brain Imaging in Health and disease”. Fourth IBRO World Congress of Neuroscience, Kyoto, Japan, 1995.

12. The role of the prefrontal cortex in memory retrieval. The Annual Meeting of the Clinical Research

Society, Toronto. 1995. 13. Left prefrontal dysfunction in schizophrenia using cognitive activations - beyond the WCST.

International Congress on Schizophrenia Research. Published in Schizophrenia Research Vol 15, page 86, 1995


14. Schizophrenia and its treatment: Lessons from PET imaging. Invited speaker - Department of

Psychiatry, Mt. Sinai School of Medicine, New York, USA. April 1996. 15. SDA Antipsychotics: from theory to clinical practice - Lessons from PET neuroimaging. XXth CINP

Congress. Melbourne, Australia, 1996. 16. What is the lowest effective dose of haloperidol? Evidence from PET studies. Biological Psychiatry.

1996;39(7):513. 17. Is Loxapine an 'atypical' antipsychotic: A PET study of the in vivo 5-HT2 and D2 occupancy.

European Neuropsychopharmacology. 1996;6 (Suppl. 3):72. 18. A comparison of the different approaches to measure D2 dopamine receptors using PET. 19th

Annual Meeting of the Canadian College of Neuropsychopharmacology. Toronto: CCNP, Toronto; 1996: 29.

19. What is the lowest effective dose of haloperidol: Lessons from PET neuroimaging. Presented at the

Annual meeting of the Canadian Psychiatric Association, Quebec City. October 2, 1996. 20. The treatment of schizophrenia – Lessons from PET imaging. Invited symposium speaker. III Pan-

Pacific Conference on Brain Topography, Tokyo, Japan, 1997. 21. Antipsychotics: from theory to clinical practice - Lessons from PET neuroimaging. Grand Rounds,

National Institute of Mental Health Center for Clinical Neurosciences – St. Elizabeth’s Hospital. Washington DC, USA, 1997.

22. The treatment of schizophrenia – What can we learn from PET imaging. University Grand Rounds,

Department of Psychiatry, University of Ottawa, Canada, 1997. 23. Bridging theory to clinical practice via PET occupancy studies of antipsychotics. Invited symposium

speaker, Joint meeting of the BAP-CCNP, Cambridge, UK, 1997. 24. Bridging theory to clinical practice via PET occupancy studies of antipsychotics. Invited satellite

symposium speaker. Annual meeting of the CPA, Calgary, Canada, 1997. 25. PET studies – Lessons for the clinician. Schizophrenia – 2nd Annual Update. Whitby Mental Health

Centre, Canada, 1997. 26. PET studies of schizophrenia – clinical implications. Satellite Symposium to the Annual Meeting of

the Canadian Psychiatric Association, Calgary, Canada, 1997. 27. The clinical treatment of schizophrenia – from theory to practice. The Atlantic Think-Tank on

Schizophrenia Meeting. Halifax, Canada, 1997. 28. A new classification of antipsychotics based on 5-HT2/D2 receptor imaging. Syllabus of the 150th

APA Annual Meeting, San Diego. Page 80. 1997. 29. Role of the prefrontal cortex in human episodic memory – lessons from PET imaging. Symposium

speaker. 6th World Congress of Biological Psychiatry, Nice, France, 1997.


30. Does loxapine plus cyproheptadine make clozapine: evidence from PET imaging. Oral

presentation. 6th World Congress of Biological Psychiatry, Nice, France, 1997. 31. The clinical treatment of schizophrenia – from theory to practice lessons from PET imaging. Invited

speaker to the Annual meeting of the Czech and Slovak College of Neuropsychopharmacology, Jesenik, Czech Republic, 1998.

32. How brain imaging changes our view of the human mind and mental illness. The JPS Robertson

Memorial Lecture, Department of Psychology, Trent University, Peterborough, Canada, 1998. 33. How PET imaging can guide the dosing of antipsychotics – lessons from the study of

schizophrenia. Invited speaker 99th Annual meeting of the American Society of Clinical Pharmacology and Therapeutics, New Orleans, USA, 1998.

34. PET imaging of Schizophrenia – from the Scanner to the Bedside. Grand Rounds, Department of

Psychiatry, McMaster University, Canada, 1998. 35. What PET imaging has to tell us about the treatment of schizophrenia: neuroreceptor imaging

studies using PET. Research Seminar. Department of Psychiatry, McGill University, Canada 1998. 36. PET studies of 5-HT2 receptors in Schizophrenia: Implications for etiology and therapeutics. Invited

Symposium Speaker. 21st Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, Canada, 1998.

37. The neurobiology of Episodic Memory – PET Studies. Behavioural Neurosciences Seminar,

Department of Psychology, University of Waterloo, Canada, 1998. 38. What PET imaging can tell us regarding antipsychotic treatment. Invited speaker to the

International Consensus Conference on Late Onset Schizophrenia. Leeds Castle, England, 1998. 39. The mechanism of action of antipsychotics: Lessons from PET imaging. Grand Rounds, Dept. of

Psychiatry, Medical College of Virginia, Richmond, USA, 1998. 40. PET imaging of Antipsychotics: From the scanner to the bedside. Plenary Lecture,

Psychopharmacology 2000 Conference, Toronto, Canada, 1998. 41. Are atypical antipsychotics all the same: Lessons from PET imaging. Plenary Lecture,

Schizophrenia 98, Toronto, Canada, 1998. 42. PET imaging of Antipsychotics: From the scanner to the bedside. Grand Rounds, Dept. of

Psychiatry, University of Saskatchewan, Saskatoon, Canada, 1998. 43. Brain imaging of Antipsychotics: From the scanner to the bedside. Invited speaker. 15th Annual

Pittsburgh Schizophrenia Conference, University of Pittsburgh Medical Centre, Pittsburgh, USA, 1998.

44. Is amoxapine an atypical antipsychotic? Supportive PET evidence. Poster presentation. Annual

Meeting of the Society of Biological Psychiatry, Toronto, 1998.


45. The receptor occupancy of olanzapine assessed with PET: theoretical and clinical implications. Poster presentation. Annual Meeting of the Society of Biological Psychiatry, Toronto, 1998.

46. Relationship Between Dose and Dopamine D2 Occupancy of Typical and Atypical Antipsychotics -

Implications for Comparisons. XXIst meeting of the Collegium Internationale Psychopharmacologicum (CINP), Glasgow, 1998.

47. Drug-induced movement disorders in Schizophrenia: Lessons from PET imaging. Invited Speaker.

Conference on Movement Disorders: Diagnosis and Management. Lake Louise, Canada. 1999. 48. Antipsychotic treatment of first episode of schizophrenia: Lessons from the scanner to the Bedside.

Plenary speaker at the Millennium Conference on Psychosis in Youth organised by the Dept. of Psychiatry, University of Western Ontario, London, Canada. 1999.

49. The treatment of schizophrenia – lessons from PET imaging. Grand Rounds, Douglas Hospital,

Montreal, Canada. 1999. 50. The treatment of schizophrenia – lessons from PET imaging. Grand Rounds, Louis H Lafontaine

Hospital, Montreal, Canada. 1999. 51. The treatment of schizophrenia – lessons from PET imaging. Grand Rounds, St. Mary’s Hospital,

Montreal, Canada. 1999. 52. New Thoughts on an old receptor: the role of dopamine D2 receptors in antipsychotic action.

Special Award Lecture to the Canadian College of Neuropsychopharmacology, Halifax, Canada, 1999.

53. Do receptor studies really help us deal with real patients? Symposium on the Neurobiology of First

Episode Psychosis. London, UK, 1999. 54. What PET studies tell us about the treatment of schizophrenia. Plenary speaker at the

Schizophrenia 2000 Conference organized by the Dept. of Psychiatry, University of Alberta, Edmonton, Canada. 1999.

55. The treatment of schizophrenia – lessons from PET imaging. Plenary speaker at the Mexican

Congress of Psychiatry, Huatulco, Mexico, Canada. 1999. 56. What PET studies tell us about the treatment of schizophrenia. Grand Rounds, Riverview Hospital,

Vancouver, Canada. 1999. 57. What PET studies tell us about the treatment of schizophrenia. Grand Rounds, University Hospital,

University of British Columbia, Vancouver, Canada. 1999. 58. Does D2 occupancy predict antipsychotic response and side-effects: a randomised double-blind

test of the hypothesis. International Congress for Schizophrenia Research, Santa Fe, 1999. 59. Prolonged receptor occupancy after a single dose of antipsychotics -- Do we really need to give

these drugs everyday? American College of Neuropsychopharmacology, Acapulco, Mexico, 1999. 60. Transience and Looseness: Some irreverent thoughts regarding the mechanism of action of


atypical antipsychotics. Research Seminar. Wyeth Ayerst Research. CNS Division. King of Prussia, USA. 2000.

61. What PET receptor studies tell us about the treatment of schizophrenia: New Findings and New

Directions. Invited speaker at the Third Annual CNS Summit, Scottsdale, USA. 2000. 62. What is atypical about atypical antipsychotics - Lessons from PET imaging. University Rounds,

Department of Psychiatry, Dalhousie University, Halifax, Canada. 2000. 63. Looseness and Transience – some irreverent ideas about what makes an antipsychotic atypical.

Seminar at the Department of Pharmacology, Dalhousie University, Halifax, Canada. 2000. 64. Clinical pharmacology of antipsychotics – lessons from PET imaging. Invited presentation in the

Workshop entitled “Schizophrenia: Pathological bases and mechanism of antipsychotic action.” Organised by Institut de Recherches Internationales Servier, Chicago, USA, 2000.

65. Looseness and Transience but not Promiscuity – some atypical ideas about what makes an

antipsychotic atypical. Seminar at the Smith Kline Beecham research group in Experimental Medicine, Cambridge, England, 2000.

66. PET studies of serotonin receptors in Schizophrenia: Implications for pathophysiology and

therapeutics. Presented at the XXIInd Meeting of the CINP, Brussels, Belgium, 2000. 67. Neurobiology of Schizophrenia and PET Imaging: Implications for Relapse Prevention and Long-

Term Management. Scientific Symposium Talk at the Annual Meeting of the Canadian Psychiatric Association, Victoria, Canada, 2000.

68. Receptor Occupancy Studies of Antipsychotics – What can these studies tell you that a test-tube

can’t? Invited talk at the Society of Nuclear Imaging in Drug Development Meeting, Bethesda, USA, 2000.

69. What is “atypical” about atypical antipsychotics – lessons from bench to bedside. Invited Speaker at

the Advances in the Treatment of Schizophrenia Conference, Montefiore Medical Centre, Albert Einstein College of Medicine, New York, USA, 2000.

70. What is “atypical” about atypical antipsychotics – lessons from bench to bedside. Grand Rounds,

Dept. of Psychiatry, Michigan State University, Lansing, USA, 2000. 71. What is “atypical” about atypical antipsychotics – perspectives from PET imaging and

Pharmacology. Invited Speaker, 3rd University of Michigan Schizophrenia Colloquium, Ann Arbour USA, 2000.

72. What makes an atypical antipsychotic “atypical”: A synthesis from a receptor occupancy

perspective. Invited Speaker, Symposium on the Neurobiology of Schizophrenia and New Developments in the role of Atypical Antipsychotics, Key West, Florida, USA, 2000.

73. What makes an atypical antipsychotic “atypical”: lessons from bench to bedside. Invited Speaker in

“Meet the Expert in Psychopharmacology Series”, Utrecht, Netherlands, 2000. 74. Transient Occupancy at D2 Receptors: A new hypothesis for atypical antipsychotics. Presented at


the 55th Annual Scientific Meeting of the Society for Biological Psychiatry, Chicago, 2000. 75. Are animal studies of antipsychotics appropriately dosed?. Presented at the 55th Annual Scientific

Meeting of the Society for Biological Psychiatry, Chicago, 2000. 76. Fast koff at the dopamine D2 receptor (Not high affinity at other receptors) is the key to clozapine’s

uniqueness and atypical antipsychotic activity. Presented at the XXIInd Meeting of the CINP, Brussels, 2000.

77. What is really atypical about ‘atypical’ antipsychotics: bridging test-tube findings and PET studies.

Fourth Paul Janssen Lecture. Institute of Psychiatry, London, England, 2001. 78. What is really atypical about ‘atypical’ antipsychotics: bridging test-tube findings and PET studies.

Fourth Paul Janssen Lecture. Department of Psychiatry, University of Cambridge, England, 2001. 79. What is really atypical about ‘atypical’ antipsychotics: bridging test-tube findings and PET studies.

Fourth Paul Janssen Lecture. Department of Psychiatry, University of Manchester, England. 2001. 80. What is really atypical about ‘atypical’ antipsychotics: lessons from PET Imaging. Plenary Session

Speaker. Eighth International Congress on Schizophrenia Research, Whistler, Canada. 2001. 81. What is really atypical about ‘atypical’ antipsychotics: lessons from PET Imaging. Invited Speaker,

APA-CME Symposium, Annual Meeting of the American Psychiatric Association, New Orleans. 2001.

82. What is really atypical about ‘atypical’ antipsychotics: lessons from PET Imaging. Grand Rounds,

Long Island Jewish Hospital, Albert Einstein College of Medicine, New York, 2001. 83. Is D2 antagonism the sole mechanism of antipsychotic effect? – A Debate. Mental Health Forum.

Prof. Tim Crow, Chairman. London, England, 2001. 84. What is really atypical about ‘atypical’ antipsychotics: lessons from PET Imaging. Grand Rounds,

VAMC, Pittsburgh, USA. 2001. 85. How antipsychotics work: lessons from men, mice and molecules. Keynote Speaker for Research

Day, Western Psychiatric Institute and Clinic, University of Pittsburgh, UPMC, Pittsburgh, USA. 2001.

86. Linking the biology, psychology and pharmacology of schizophrenia: a feasible project or just a

delusion? Keynote Speaker for the 27th Annual Harvey Stancer Research Day, Dept. of Psychiatry, University of Toronto, Canada. 2001.

87. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Invited

Synthesium Speaker, 34th International Congress of Physiological Sciences, Christchurch, New Zealand, 2001.

88. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or just a

delusion? Seminar in Neuropsychiatry, Department of Psychiatry, University of Western Ontario, London, Canada. 2001.


89. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or just a delusion? Centre for Studies in Behavioural Neurobiology, Concordia University, Montreal , Canada. 2001.

90. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Invited

Neuropsychiatry Research Seminar Speaker, Johns Hopkins University, Baltimore, USA, 2001. 91. Fast koff at the dopamine D2 receptor (Not high affinity at other receptors) is the key to atypical

antipsychotic activity. Poster presented at the Eighth International Congress on Schizophrenia Research, Whistler, Canada. 2001.

92. Typical and Atypical antipsychotics: Affinity and Occupancy at dopamine D2 receptors. Symposium

Speaker. 7th World Congress of Biological Psychiatry, Berlin, 2001. 93. Dopamine D2 receptor modulation – necessary and sufficient for atypical antipsychotic effect.

Panel Session. 40th Annual Meeting of the ACNP, Hawaii, USA, 2001. 94. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Seminar in

Neurosciences, Queens University, Kingston, Canada, 2002. 95. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or just a

delusion? Workshop, Annual Meeting of the International Neuropsychological Society, Toronto, Canada, 2002.

96. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Seminar in

Clinical Neuropsychiatry. University of Pennsylvania, Philadelphia, 2002. 97. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Grand

Rounds in Psychiatry, Hahnemann University – Drexel University, Philadelphia, USA, 2002. 98. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Seminar in

Neurobiology. Yale University, New Haven, USA, 2002. 99. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Seminar in

Pharmacology. McGill University, Montreal, Canada, 2002. 100. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or just

a delusion? Invited Talk, 12th Annual Conference of the Rotman Research Institute: Emotions and the Brain, Toronto, Canada, 2002

101. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Research

Seminar at Centre De Recherche Université Laval Robert-Giffard, Quebec, Canada, 2002. 102. What is atypical about atypical antipsychotics? The image becomes clearer. Plenary Speaker at

“Mind Matters – the 2nd International Forum on Schizophrenia, Warsaw, Poland. 103. Since we getting close to preventing schizophrenia and curing the illness in 2025 none of the

topics in this forum be valid? “Mind Matters – the 2nd International Forum on Schizophrenia,


Warsaw, Poland. 104. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Grand

Rounds, Department of Psychiatry, SUNY at Buffalo, New York, USA. 2002 105. Half a century of antipsychotics and dopamine D2 receptor modulation is still necessary and

sufficient for atypical antipsychotic effect. [Co-Chairman of the Meeting]. Dopamine in the pathophysiology and therapeutics of schizophrenia: new findings, new directions – International Expert Meeting, Montreal, Canada, 2002.

106. Half a century of antipsychotics and dopamine D2 receptor modulation is still necessary and

sufficient for atypical antipsychotic effect. Dopamine 2002. Portland, USA, 2002. 107. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Research

Seminar, Department of Psychiatry, Universite Louis Pasteur Strasbourg, Strasbourg, France. 2002.

108. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or

just a delusion? Invited Talk, National Institute of Psychiatry, Mexico DF, Mexico, 2002. 109. Why are antipsychotics anti”psychotic”? – speculations regarding fundamental mechanisms.

Guest Lecture in Psychopharmacology and Neurobiology Series, Massachusetts Mental Health Centre, Boston, USA. 2002.

110. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or

just a delusion? Invited Talk, University of Montreal – Louis H Lafontaine Hospital, Montreal, Canada, 2002.

111. From dopamine to salience to psychosis – why antipsychotics are anti-“psychotic.” Invited Talk at

the “Schizophrenia - Challenging the Orthodox” Conference, Institute of Psychiatry, London, UK, 2002.

112. Linking the biology, phenomenology and pharmacology of schizophrenia: a feasible project or just

a delusion? Invited Seminar – Department of Psychology, University of Michigan, Ann Arbour, USA. 2002.

113. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Feldman

Lecture, Department of Psychiatry, Grey Nun’s Hospital, Edmonton, Canada. 2002. 114. Psychosis as a disorder of dopamine-induced aberrant salience – a framework linking the biology,

phenomenology and pharmacology of Schizophrenia. Society for Biological Psychiatry, Philadelphia, USA, 2002

115. PET Imaging Studies of Atypical Antipsychotics – Implications for dosing and mechanism of

action. American Psychiatric Association, Philadelphia, USA, 2002. 116. Dopamine D2 receptor modulation – necessary and sufficient for atypical antipsychotic effect.

Symposium Speaker. European Conference on the Biology of Psychosis, Copenhagen,


Denmark, 2002. 117. Why are antipsychotics anti-psychotic? Speculations regarding critical mechanisms.

Symposium Speaker. European Conference on the Biology of Psychosis, Copenhagen, Denmark, 2002.

118. Motivational salience – the variable linking dopamine, psychosis, antipsychotics. 41st Annual

Meeting of the American College of Neuropsychopharmacology, San Juan, Peurto Rico, USA, 2002.

119. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Grand

Rounds in Psychiatry, Michael Reese Hospital, Chicago, USA. 2003. 120. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Grand

Rounds in Psychiatry, University of Illinois, Chicago, USA. 2003. 121. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Grand

Rounds in Psychiatry, Duke University, Durham, USA. 2003. 122. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Washington

University Antipsychotics Conference, St. Louis, USA. 2003. 123. How do dopamine and salience fit into the “big picture” of Schizophrenia? Plenary Session.

International Congress of Schizophrenia Research, Colorado Springs, USA. 2003. 124. From dopamine to salience to psychosis – understanding why antipsychotics are anti-"psychotic".

XXVth symposium of the CRSN, Montreal, Canada. 2003 125. What can PET receptor imaging contribute to understanding the treatment of psychosis?

Workshop on Brain Imaging and Psychosis. Society for Human Brain Mapping Conference. New York. USA. 2003.

126. Why are neurolpetics anti"psychotic" - thoughts regarding critical mechanisms. Meeting of the

British Association of Psychopharmacology. Cambridge, England. 2003. 127. Linking Biology, Phenomenology and Pharmacology in Psychosis – A feasible project or just a

delusion? Ham Symposium, Department of Psychiatry, University of North Carolina. Raleigh. USA. 2003.

128. How do dopamine and salience fit into the “big picture” of Schizophrenia. International

Congress on Schizophrenia Research, Colorado Springs, USA. 2003. 129. Motivational salience – the variable linking dopamine, psychosis, antipsychotics.

International Congress on Schizophrenia Research, Colorado Springs, USA. 2003. 130. How antipsychotics work - the story of dopamine, salience and psychosis. Grand Rounds, Mt.

Sinai School of Medicine, New York, USA. 2004.


131. How antipsychotics work - the story of dopamine, salience and psychosis. Grand Rounds, Cornell

University School of Medicine, New York, USA. 2004. 132. How antipsychotics work - the story of dopamine, salience and psychosis. Grand Rounds,

McLean Hospital, Harvard Univeristy, Boston, USA. 2004. 133. From receptors to response – thoughts on the mechanism of action of antipsychotics. The Lake

Ridge Hospital Neuroscience in Psychiatry Conference, Niagara-On-The-Lake, Ontario, Canada, 2004.

134. From receptors to response – thoughts on the mechanism of action of antipsychotics. Department

of Neuropsychiatry, Keio University, Tokyo, Japan, 2004. 135. From receptors to response – thoughts on the mechanism of action of antipsychotics. Kyoto

Round Table of the Otsuka CNS Discovery Group, Kyoto, Japan, 2004. 136. From receptors to reality – linking the brain and mind in the study of schizophrenia. Annual

Meeting of the Institute of Neurosciences, Mental Health and Addictions, Ottawa, Canada, 2004 137. Dosing with antipsychotics – lessons from occupancy studies of men and mice. Satellite

Symposium. American Psychiatric Association, New York, USA, 2004. 138. From dopamine to salience to psychosis – understanding why antipsychotics are anti-

"psychotic". Satellite Symposium. American Psychiatric Association, New York, USA, 2004 139. Immediate onset of anti“psychotic” effect - the early onset hypothesis. Society for Biological

Psychiatry, New York, USA, 2004. 140. From receptors to response – thoughts on the mechanism of action of antipsychotics.

Presentation to the Canadian College of Neuropsychopharmacology, Kingston, Canada, 2004. 141. How do dopamine blockers become anti 'psychotic?' – speculations regarding critical

mechanism. Presentation to the CINP, Paris, France, 2004. 142. From dopamine to salience to psychosis – Linking the Biology and Phenomenology in

Psychosis. Seminar Speaker at the ECNP, Stockholm, Sweden, 2004. 143. From dopamine to salience to psychosis – Linking the Biology and Phenomenology in

Psychosis. Plenary Speaker, International Conference on Early Psychosis. Vancouver, Canada, 2004.

144. The almost immediate onset of antipsychotic activity. Co-Chair and Speaker of a Panel on

“Delayed Onset of antipsychotic action – Fact or Fiction.” American College of Neuropsychopharmacology, San Juan, Puerto Rico, 2004.

145. From Dopamine to Salience to Psychosis – Linking Biology to Phenomenology. Resident


Invitational Grand Rounds, Washington University, St. Louis. USA, 2005. 146. Delayed Onset of Antipsychotic Action – Fact or Fiction. Chair of the Panel. American College of

Neuropsychopharmacology. San-Juan, Puerto Rico, USA, 2005. 147. How atypical antipsychotics spare motor side-effects – the critical role for dopamine D2 receptors.

Invited Symposium Speaker. 9th International Congress of the Movement Disorders Society, New Orleans, USA, 2005.

148. From Dopamine to Salience to Psychosis – Linking Biology to Phenomenology. Grand Rounds,

The Zucker Hillside Hospital and the Dept of Psychiatry, Albert Einstein Medical School, New York, USA, 2005.

149. From Dopamine to Salience to Psychosis – Linking Biology to Phenomenology. Invited Seminar,

Search For Treatment in Early Psychoses (STEP) Symposium, Wayne State University, USA, 2005.

150. Imaging receptors from bench to bedside - Lessons learnt in the study of schizophrenia. Invited

Plenary Speaker – Human Brain Mapping Conference, Toronto, Canada, 2005. 151. How antipsychotics work – from receptors to reality. APA Satellite Symposium on “From

Molecular Insight to Clinical Outcomes: Recent Advances in Schizophrenia”. APA Annual Convention, Atlanta, USA, 2005.

152. Imaging Antipsychotics – From the Bedside to the Bench. APA Symposium. APA Annual

Convention, Atlanta, USA, 2005. 153. How antipsychotics work: lessons from imaging studies of men, mice and molecules. Presentation

to the Summer Course on Schizophrenia at the Cold Springs Harbour Laboratory, NY, USA. 2005.

154. How antipsychotics become anti-psychotic – thoughts regarding the mechanisms. Satellite

Symposium at The World Congress of Societies of Biological Psychiatry, Vienna, 2005. 155. How antipsychotics work - from receptors to reality. Invited Speaker, Japanese College of

Neuropsychopharmacology, Tokyo, Japan, 2005. 156. From Dopamine to Salience to Psychosis – Linking Biology to Phenomenology. Invited Speaker

at the CCNP Symposium: Role of dopamine in disorders of motivational salience: from bench to bedside. 18th ECNP Congress, Amsterdam, Netherlands, 2005.

157. From receptor occupancy to response - thoughts on the mechanism of action of antipsychotics.

Invited Satellite Symposim Speaker. 18th ECNP Congress, Amsterdam, Netherlands, 2005. 158. From Dopamine to Salience to Psychosis – A feasible project or just a delusion. Invited Speaker

at the Monthly Rounds of the New York Psychoanalytic Institute, NY, USA. 2005.


159. How antipsychotics work: from receptors to reality. Invited speaker at the Conference on 'Dopamine, computation and salience', Douglas Hospital Research Centre, Montreal, Canada. 2005.

160. The early onset hypothesis of antipsychotic action. Co-Chair and Speaker of a

Symposium on “The Delayed Onset Of Antipsychotic And Antidepressant Action - Where's The Delay?” The World Congress of Societies of Biological Psychiatry, Vienna, 2005.

161. Blocking D2 receptors to get antipsychotic response – which ones, when and why? Co- Chair

and Speaker of a Symposium on “Antipsychotics And Neurotransmitter Receptors: Beyond Simple Striatal D2 Occupancy” The World Congress of Societies of Biological Psychiatry, Vienna, 2005.

162. Modeling antipsychotic action - convergence from studies of mice and men. Co- Chair

and Speaker of a Panel on “Animal models of Schizophrenia – Making Progress or Just a Delusion,” American College of Neuropsychopharmacology, Hawaii, USA, 2005.

163. Understanding antipsychotic action via imaging - lessons from the bench to the bedside. Invited

Speaker, 2006 Annual Conference of the Academy of Molecular Imaging, Florida, USA, 2006. 164. Linking the Biology and Phenomenology of Psychosis - a Feasible Project or just a Delusion.

Invited Speaker. WPA Juan J. Lopez Ibor Centennial Congress. Madrid, Spain, 2006. 165. How Antipsychotics work - From Receptors to Reality. Invited Speaker. WPA Juan J. Lopez Ibor

Centennial Congress. Madrid, Spain, 2006. 166. Antipsychotic drugs and D2 - new surprises from an old receptor. Invited Speaker 47th Annual

Meeting of the SCNP, Helsingor, Denmark, 2006. 167. How antipsychotics work – from receptors to reality. Honorary Lecture. 47th Annual Meeting of

the SCNP, Helsingor, Denmark, 2006. 168. From dopamine to delusions - understanding psychosis from the bench to the bedside. Satellite

Symposium. American Psychiatric Association. Toronto, Canada, 2006. 169. Redefining the occupancy-response relationship. 13th Winter Workshop on Schizophrenia.

Davos. Switzerland, 2006. 170. No delay in the onset of antispychotic effect - impact on theory and preclinical models. Society for

Biological Psychiatry, Toronto, 2006. 171. How Antipsychotics work - From Receptors to Reality. Invited Speaker. Annual Meeting of the

SOPSI (Italian Society of Psychopathology). Rome, Italy, 2007. 172. How Antipsychotics work - From Receptors to Reality. Grand Rounds, Yale University, USA.

March, 2007.


173. Predicting antipsychotics – Linking classical preclinical models and clinical effects. Symposium Presentation, Society for Biological Psychiatry, San Diego, 2007.

174. Imaging the ‘high states’ of the dopamine D2/D3 receptor with [11C]-PHNO – the effect of

schizophrenia and antipsychotics. Symposium Presentation, Society for Biological Psychiatry, San Diego, 2007.

175. Linking the Biology and Phenomenology of Psychosis - a Feasible Project or just a Delusion.

Invited Plenary Speaker. Italian Society of Biological Psychiatry, Naples, Italy, 2007. 176. How Antipsychotics work - From Receptors to Reality. Invited Plenary Speaker. XIth Spanish

National Congress of Psychiatry, Santiago De Compostela, Spain. 2007. 177. From dopamine to delusions - understanding psychosis from the bench to the bedside. Plenary

speaker. Maudsley Mediterranean Forum, Palermo, Italy. 178. How Antipsychotics work - From Receptors to Response. Plenary Speaker. European Congress of

Neuropsychopharmacology (ECNP), Vienna, Austria, 2007. 179. Dopamine, salience and psychosis. Plenary talk at the International Conference on Early Phase of

Psychosis – Research and Treatment. London, UK. 2007 180. What do we want to see in brain Imaging. Moderator and Discussant section on “Molecules and

Cells”. Conference organized by the New York Academy of Sciences in London, UK. 2007 181. How antipsychotic medications work - from receptors to response. Zangwill Club Lecture,

Cambridge, UK, 2008. 182. "How psychosis responds to different treatments - across time, across stages, across borders"

Organized Poster Trek. Winter Workshop in Schizophrenia. Montreaux. Switzerland, 2008. 183. How Antipsychotics Work-Images And Insights Form Bench To The Bedside. Plenary Lecture.

Symposium Advances in Psychiatry. Madrid, Spain, 2008 184. The mechanism of action of antipsychotics - linking the neurochemical to the subjective".

Universitätsklinikum Hamburg-Eppendorf, Germany, 2008. 185. Mechanisms of adjunctive anitpsychotic effects. ENCP Consensus Meeting. Nice, France, 2008. 186. How Antipsychotics Work - from Receptors to Response. Centre for Neurosciences and

Schizophrenia Research, Copenhagen, Denmark, 2008. 187. From dopamine to delusions - understanding psychosis from the bench to the bedside. Invited

Lecture, Institute of Mental Health, Singapore. 2008. 188. How Antipsychotics Work-From Receptors to Response. 1st Professional Lecture, Chapter of

Psychiatrists, Academy of Medicine, Singapore. 2008.


189. PET Imaging in Psychosis - lessons learnt and way forward. Invited Guest Lecture. Annual

Meeting of the British Nuclear Medicine Society. Edinburgh, UK. 2008. 190. How Antipsychotics Work: From Receptors to Reality. Speaker at the Celebration Honouring

David Kupfer, University of Pittsburgh, USA. 2008. 191. From brain imaging to clinical practice in psychiatry, Annual Meeting of the Royal College of

Psychiatrists, London, UK. 2008. 192. Antipsychotics – where to we stand. Speaker at the Pfizer-sponsored satellite symposium, CINP,

Munich, Germany, 2008. 193. D2 blockade and antipsychotic response how much - how fast - how long. Organon-sponsored

satellite symposium, Annual Meeting of the British Association of Psychopharmacology, Harrogate, UK, 2008.

194. "If antipsychotics work for most conditions - what does it mean for mechanisms of illness and drug

action?" Study group speaker. American College of Neuropsychopharmacology. Scottsdale, USA, 2008.

195. How antipsychotics work. From receptors to reality. Symposium on Brain Imaging, Copenhagen

University Hospitals, Copenhagen, Denmark, 2009. 196. How Antipsychotics Work-From Receptors to Response. Invited Lecture to Discovery

Pharmacology Research, Lundbeck, Copenhagen, Denmark, 2009. 197. Linking dopamine to salience to psychosis – a useful idea or just another delusion? Invited lecture

to the British Neuropsychiatric Association, London, UK, 2009. 198. Early Sensitivity to Treatment as a Predictor of Long Term Outcome. Eli-Lilly sponsored

conference on Schizophrenia is a Changing Illness: Debate and Comment . London, UK, 2009. 199. Psychosis and Cognition in Schizophrenia - Where Have We Been, Where Should We Be Going.

Barrett Lecture, University of Michigan, Ann Arbor, USA. 2009. 200. How Antipsychotics Work-From Receptors to Response. Invited speaker at the National Scietific

Conference of the Mental Health Research Network, Nottingham, UK, 2009. 201. Schizophrenia, Psychosis and Cognition – Back to the Future. Invited speaker at the National

Scietific Conference of the Mental Health Research Network, Nottingham, UK, 2009. 202. Schizophrenia, Psychosis and Cognition. Annual Meeting of the Royal College of Psychiatrists,

Leeds, UK. 2009. 203. Implications of early response and non-response in schizophrenia. Lundbeck sponsored satellite

symposium at the World Federation of Biological Psychiatry, Paris, 2009.


204. Schizophrenia, Psychosis and Cognition – Back to the Future. Plenary Lecture, British Association

of Psychopharmacology, Oxford, UK, 2009. 205. How antipsychotics work – From receptors to reality. Plenary Lecture. European Society for

Behavioural Pharmacology. Rome, Italy, 2009. GRADUATE STUDENTS SUPERVISED Supervisor Paul Morrison (PhD) 2008 - Present Michele Korostil (MS) 2005 - 2007 Romina Mizrahi (PhD) 2004 – 2007 David Mamo (MS) 2001 – 2003 Jeff Daskalakis (PhD) 1998 – 2002. Co-supervisor Suzanne So (PhD) 2008 – Present Tiago Marques (PhD) 2008 - Present Francoise Ko (PhD) 2001 – 2005 Committee Membership Karen Korth (PhD) 2002 - 2007 Peter Turrone (PhD) 2001 - 2004. Ed McNamma (MS) 2002 - 2004. Bob Mehta (MS) 2001 - 2002.


RESEARCH TRAINEES SUPERVISED

Research Resident Positions [Special 6-12 month research rotation for residents, University of Toronto] Ralph Lewis, MD 1995 5-HT2 studies in schizophrenia Cindy Fu, MD 1996 Clonidine challenges Jeff Meyer, MD 1996 5-HT2 studies in depression Jeff Daskalakis, MD 1998 D2 PET and Transcranial Magnetic Stim. Studies Michael Kiang, MD 2000 Biology of Negative Symptom Expression Michele Korostil 2004 Emotional Stroop in Schizophrenia Alan Kahn, MD 2004 Clinician-Scientist Stream - Imaging Jonathan Downar, MD, PhD 2005-2006 Clinician-Scientist Stream - Imaging Post-doctoral Fellows/Junior Scientists Supervised/Mentored Janine Jennings, PhD 1995-1997 Funded by the Rotman Research Institute Studies using O15-H2O Imaging in Schizophrenia. Raymond Cho, MD 1997-1998 Funded by the William T Hunter Foundation 5-HT2 receptors in atypical antipsychotics and antidepressants. Ralph Lewis, MD 1996-1998 Funded by the OMHF 5-HT2 receptors in schizophrenia. Simone Fauth-Silvestri, MD, PhD 1997-1998 Funded by The Clarke Institute Foundation D2 receptor upregulation with antipsychotics. Marie-Louise Wadenberg, PhD 1998 –2000 Funded by Zyprexa Fellowship in Schizophrenia Contribution of different receptors subtypes of atypical antipsychotic action. Paul Fitzgerald, MD 1998-1999 Funded by Monash University, Victoria, Australia Haloperidol plasma levels and D2 occupancy. Pierre Vidailhet, MD, PhD 1998-2000 Funded by INSERM, 405, Strassbourg, France Pharmacological modulation of cognition in schizophrenia. Johannes Tauscher, MD 1999-2001 Funded by the Shroedinger Fellowship, Austria 5-HT1A receptors in Schizophrenia NPLG Verhoeff, MD, PhD 1999-2001 Funded by OMHF and NARSAD Endogenous dopamine in Schizophrenia Jeff Daskalakis, MD 1999-2001 Funded by OMHF Trancranial Magnetic Stimulation in Schizophrenia Nathalie Ginovart, PhD 2000-2002 Funded by NARSAD


Dopamine Receptor Upregulation by Antipsychotics. Wenshan Sun, PhD 2000-2002 Grant Funded Dopamine Receptors and Imaging in small-animals using MicroProbe Catherine Tenn, PhD 2000-2005 Funded by OMHF Sensitisation based animal model of Schizophrenia Jimmy Jensen, PhD 2001-2005 Funded by CIHR/NET Grant fMRI in Schizophrenia David Mamo, MD 2001-2003 Bebensee Fellowship Studies of enhanced sensitivity to antipsychotics with aging. Ming Li, PhD 2002-2005 Funded by OMHF Antipsychotics and animal models Andrew Smith, PhD 2002-2004 Funded by OMHF Neural network modeling Matthaeus Willeit, MD 2003-2005 Funded by Janssen Foundation fMRI in Schizophrenia Romina Mizrahi, MD 2003-2007 Grant Funded Symptoms in schizophrenia Pablo Rusjan, PhD 2003-2004 Funded by BRAIN program Imaging software development Sridhar Natesan, PhD 2003-2006 Grant Funded Animal models in Schizophrenia Mahesh Menon, PhD 2005-2008 Funded by CIHR/NET Grant fMRI Imaging in Schizophrenia Ariel Graf MD, PhD 2004-2006 Grant Funded PET Imaging in Schizophrenia Robert Featherstone 2004-2007 Grant Funded Behavioural and Cognitive animal models of Schizophrenia Julia Savina 2004-2004 Grant Funded fMRI in Schizophrenia Ofer Agid 2001-2004 Grant Funded The time to onset of antipsychotic effects Anna-Noel Samaha, PhD 2005-2008 CIHR Funded Effects of chronic treatment on D2-High states


Hiroyuki Uchida, MD, PhD 2005-2008 Japanese Soc. Neuropsychopharmacology. PET Imaging in the Elderly Ofer Agid, MD 2005-2007 Funded by NARSAD Young Investigator Award PET studies of the D2-High states in Schizophrenia Michele Korostil, MD 2006-2008 Grant and self-funded fMRI studies of learning in schizophrenia Paul Morrison, MBBS 2008-2012 MRC Clinical Training Fellowship THC Challenges in Schizophrenia Michalapolou Panayiota, MBBS 2008-2012 MRC Strategic. Award Funded Cognition in Schizophrenia Natesan Sridhar, PhD 2008-2012 MRC Strategic. Award Funded Preclinical Antipsychotic Models Davide Amato 2008-2009 Grant and Self Funded Preclinical Antipsychotic Models James Gilleen 2008-2010 Industry Grant Funded Subjective Wellness and Cognition in Schizophrenia

Shitij Kapur Dean and Head of School King’s College London Kapur's CV.pdf · Shitij Kapur Dean...

Documents

Transcript of Shitij Kapur Dean and Head of School King’s College London Kapur's CV.pdf · Shitij Kapur Dean...